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ABSTRACT

Most of the biological systems in nature are sustained by molecular self-assemblies
which are the finest examples of supramolecular architectures. Non-covalent interactions
are key concepts which govern these molecular assemblies. Inspired by these examples
crystal engineering emerged as an important tool in supramolecular chemistry which aids
in the invention of new molecular structures with desired properties. Understanding of
how the molecules interact at the molecular levels enables one to rationally design novel
solid forms with modulated physicochemical properties. This feature of crystal
engineering has heightened its position in materials chemistry and is currently one of the
most well studied fields for generating novel compounds with pre-defined composition
and supramolecular architectures.
One such class of compounds that has immensely attracted the scientific
community and is under continuous study for wider applications is cocrystals. The
applications include various interdisciplinary fields such as pharmaceutics, catalysis,
organic conductors, explosives etc. Distinctly on the other side, cocrystals also provide a
means to discover new supramolecular synthons which is the ultimate key to molecular
assembly. Many robust supramolecular synthons have been discovered and hierarchies
are also being developed which can serves as a design tool for cocrystal synthesis. The
Cambridge Structural Database (CSD) is an important accessory in determining the
robustness of a supramolecular synthon but, this does not preclude us from discovering
new synthons.
xi

The work presented here explores new persistent supramolecular synthons in
polyphenols utilizing the basic concepts of crystal engineering and the CSD statistical
analysis. This contribution also includes the implementation of cocrystallization for
various categories of compounds which includes nutraceuticals, pharmaceuticals and
ionic salts for the design and synthesis of molecular and ionic cocrystals.
Chapter 1 highlights how supramolecular synthon approach can be used to design
and synthesize multi-component crystals, namely, cocrystals. The role of the CSD and its
importance in crystal engineering has also been discussed. Chapters 2 and 3 focus on new
persistent supramolecular synthons in the context of nutraceuticals. The cocrystals
isolated in the study are also compared with the existing cocrystals in the CSD
supramolecularly in terms of synthon formation. These persistent supramolecular
synthons are helpful in developing hierarchies which could be utilized and applied to
similar and analogous compounds. The main feature of Chapter 4 is expanding the field
of cocrystallization by studying the properties of cocrystals. Some of the properties which
have been examined here include effects of cocrystallization on solubility and
correlations between the solubility of cocrystal with cocrystal former (CCF) and melting
point of the cocrystal. The extension of cocrystals to the active pharmaceutical
ingredients (APIs) has been explored in the context of pharmaceutical cocrystals by
selecting a BCS class IV drug, hydrochlorothiazide in Chapter 5. Chapter 6 highlights the
hybridization of organic and inorganic components for the synthesis of ionic cocrystals
and is exemplified by considering lithium salts with achiral and homochiral amino acids
for the generation of 1:1 and 1:2 cocrystals.

xii

CHAPTER 1
Supramolecular synthon approach in the design of cocrystals

1.1

Introduction

The crystal engineering1 paradigm allows for the design and remodel of solid materials
with desired physicochemical properties by utilizing non-covalent bonding. Crystal
engineering relies on the basic principles of supramolecular chemistry, chemistry beyond
the molecule, in developing novel entities by manipulating the non-covalent
intermolecular interactions.2 Hydrogen bonding, metal coordination, van der Waals
forces, hydrophobic forces, electrostatic effects and pi-pi interactions are some of the
interactions which are commonly encountered in this regard. Many of the biological
molecules are inherently sustained by molecular self-assemblies which are directed by
non-covalent interactions. Naturally occurring nucleic acids such as DNA/RNA are held
together by hydrogen bonds which clearly demonstrate how wide spread non-covalent
interactions truly are.
Although the concepts of crystal engineering were introduced by Pepinsky3 in 1955,
it was extensively utilized by Schmidt during photodimerization reactions of cinnamic
acid in the solid state.4 During the 1990’s, the growth of crystal engineering gained a
rapid momentum especially in the field of organic solids, metal-organic solids,
organometallic5 and inorganic structures.6 More recently, crystal engineering principles
have also been extended to pharmaceuticals.(need reference) Crystal engineering has

1

been defined in the late 1980’s by Gautam Desiraju as “the understanding of
intermolecular interactions in the context of crystal packing and in the utilization of such
understanding in the design of new solids with desired physical and chemical
properties”.1 The basic crystal engineering approach involves first an understanding of
how molecules interact with other molecules via intermolecular interactions and
subsequently designing a supramolecular strategy for the synthesis of novel materials
with desired properties and architecture.7 The concepts of crystal engineering can be
applied to various fields such as coordination polymers8, nanotechnology9, porous
materials for hydrogen gas storage10,11, non-linear optics (NLO)12, photographic
materials13, polymorphism14, chiral resolutions15, purification, discovering new
supramolecular synthons9(a),16,17,18 and even pharmaceutics19.
The work presented herein focuses upon crystal engineering of multiple-component
crystals with an emphasis upon the exploration of cocrystals in the context of delineation
of the reliability of hydrogen bonded supramolecular synthons and their hierarchies.
1.2

Supramolecular synthons

The term synthon was coined by Corey in the context of organic chemistry and defined as
“a structural unit within a molecule which is related to a possible synthetic operation”.20
The word was later used to describe a synthetic building block rather than retrosynthetic
fragmentation structures.21 In resemblance to this, Etter and Desiraju introduced graph
sets22 and supramolecular synthons1(b) respectively.
Etter’s graph sets were based on the graph theory for classifying hydrogen bonds
patterns into simpler notations. A graph set is denoted as

(r) where ‘G’ is a pattern

designator, ‘r’ is its degree, ‘d’ denotes the number of donors and ‘a’ the number of

2

acceptors. The pattern designator has four different assignments: S, C, R and D based on
whether hydrogen bonds are inter- or intramolecular. S (self) denotes an intramolecular
hydrogen bond whereas for intermolecular bonds, C refers to hydrogen-bonded infinite
chains, R refers to rings and D refers to non-cyclic dimers and other finite hydrogen
bonded sets. However, the representation of a particular interaction between two
functionalities using graph set notation does not provide complete information about the
type of H-bond acceptors and donors. For example an acid dimer (homosynthon) and the
acid-amide dimer (heterosynthon) are represented using

(8) graph set notation but, the

representation does not reveal that whether the H-bond motif is a result of interaction
between two different or same functionalities. This problem could be resolved using
supramolecular synthons. Supramolecular synthons are defined as “structural units within
supermolecules which can be formed and/or assembled by known or conceivable
intermolecular interactions”. Supramolecular synthons are further categorized into (a)
supramolecular homosynthon: composed of identical self-complementary functionalities
or (b) supramolecular heterosynthon: composed of different but complementary
functionalities.23,24 Generally, single-component or compounds containing the functional
groups can be sustained by supramolecular homosynthons25,26,27 whereas; supramolecular
heterosynthons28,29,30 can dominate in the presence of other competing functional groups.
Figure 1.1 (a) illustrates the supramolecular homosynthon formed by the self-assembly of
amide functionality, whereas Figure 1.1 (b) the supramolecular heterosynthon formed by
the carboxylic acid and Narom.

3

(a)

(b)

Figure 1.1 (a) Supramolecular homosynthon; (b) Supramolecular heterosynthon.

1.3

CSD - A useful tool for cocrystal design

The very first step in any crystal engineering experiment is to analyze existing crystal
structures which can be carried out efficiently by the Cambridge Structural Database
(CSD).31 The CSD is a repository for small molecule crystal structures of organic and
organometallic compounds. It is a powerful tool which aids in the identification of robust,
reliable synthons and also provides an opportunity to discover new and potential
supramolecular synthons. But, there are situations when the CSD does not have sufficient
information regarding the persistency of an underexplored or a new supramolecular
synthon. In this case, a systematic study of the intermolecular interactions occurring in
the related structures archived in the CSD coupled with experiments could possibly
address the issue. But, there is high degree of reliability and plenty of information
regarding many persistent supramolecular synthons35-43 which could be utilized in crystal
engineering experiments. The reliability of CSD in designing a crystal engineering
experiment was rightly quoted by Allen and Kennard as:
‘‘the systematic analysis of large numbers of related structures is a powerful
research technique, capable of yielding results that could not be obtained by any other
method.’’32

4

The physicochemical properties of compounds inherently depend on the
arrangement of molecules in the crystal structure and thus by pre-designing the
arrangement of these molecules, the properties can be tailored. Especially, pre-designing
the arrangement of molecules in multi-component crystals via supramolecular synthons
when there are two or more than two different components is quite challenging. In this
context utilization of the CSD in generating multi-component systems, namely cocrystals,
is of great importance. However, the statistics obtained from the CSD cannot rule out the
possibility of unexplored supramolecular synthons which are persistent enough to be
considered as robust supramolecular synthons. Thus, the reserve of information in the
CSD coupled with systematic experimental study could be utilized in addressing the
hierarchy of supramolecular heterosynthons in the context of cocrystals.
1.4

Design of cocrystals

A detailed understanding of the supramolecular chemistry of the hydrogen bond acceptor
and donor moieties in a given molecule and the selection of compounds (cocrystal
formers) that are capable of forming complementary hydrogen bonds with a given
molecule play an important role in the synthesis of cocrystals. Since cocrystals are multicomponent crystals overcoming the intermolecular interactions of the individual starting
components (e.g. A…A, B…B). Stronger hydrogen bonds that form between the individual
components (A…B) dictate the formation of the cocrystal. According to Fabian:
“it is important to note that the formation of a supramolecular synthon is dictated by the
strength of hydrogen bond formed between the given molecule and the cocrystal former
rather than the number of hydrogen bond acceptors or donors present”.33
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But, this does not mean that cocrystals with supramolecular homosynthons do not
exist. Consequently, two different approaches could be utilized for the design of
cocrystals. The first approach is breaking of the supramolecular homosynthon by utilizing
a robust supramolecular heterosynthon (Figure 1.2 (a)).34 The second approach involves
the use of the peripheral H-bond donors/acceptors wherein the cocrystal is sustained by
supramolecular homosynthon as well as the heterosynthon (Figure 1.2 (b)).

(a)

(b)
Figure 1.2 (a) Supramolecular heterosynthon formed in cocrystal UNIBAU (b) Supramolecular
homosynthon and heterosynthon formed in cocrystal UNIZAO.

Several systematic studies utilized the first approach which includes supramolecular
heterosynthons hydroxyl-pyridine,35 aminopyridinium-carboxylate,36 pyridine-acid,37,38
6

amide-acid,39,40,41 acid-chloride,42 and carboxylates-weakly acidic hydroxyl moieties43
have been conducted in detail to examine the reliability of the synthon in cocrystal
design. This chapter in particular focuses on key supramolecular synthons formed by the
functionalities present in p-coumaric acid, hydrochlorothiazide and polyphenols with
other functionalities to determine the reliability and robustness of the synthon.
1.5

CSD analysis

1.5.1

General CSD Data Tables: The data tables were generated by using Conquest

version 1.14 (Feb 2012 update) of 2012 release of CSD. During the searches the
following constraints were applied: only organics, no ions (for synthons not involving
ionic moieties), 3D coordinates, not disordered, no errors. Initial contact distances used to
generate the histograms for each supramolecular synthon were well beyond the sum of
the van der Waals radii of the hydrogen bond donor and the acceptor atom.

Figure 1.3 Histogram for (acid) H-O···Narom supramolecular heterosynthon.
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The cut-off ranges for the H-bond distances were determined by looking at the H-bond
interactions in the structures from the histogram (Figure 1.3). Two searches were
conducted namely (a) raw and (b) refined for every supramolecular synthon. The raw
search was carried out between two functional groups in the presence of other competing
functionalities whereas the refined search was done in the absence of other competing
functionalities.
Tables 1.1, 1.2, 1.3, 1.4 and 1.5 list the statistics obtained from the CSD for
various supramolecular synthons for carboxylic acid (COOH), phenolic hydroxyl (PhOH), 1o & 2o sulfonamides (SO2NHR) and 2o phenyl amine (PhNHR) moieties with
other functionalities such as six membered aromatic nitrogen (Narom), 1o & 2o amide
(CONHR), 1o & 2o amine (NHR), carbonyl (C=O), ethers (C-O-C), cyano (CN), nitro
(NO2), chloride (Cl-), carboxylate (COO-) and water (H2O). The CSD analysis is
confined to certain functional groups which belong to certain target compounds that have
been a part of study in the later chapters of this dissertation.
The terms which have been used in the tables are as follows:
Example: Search for functional moiety X.
(i)

Pro-synthon (Y) = the other functional moiety

(ii)

# both = No. of hits that contain both the functional groups X & Y;

(iii)

With “biological activity” or “drug” = No. of hits with which have any kind of
biological activity (therapeutic activity) or is a medicinal drug

(iv)

# Hetero = No. of hits that form the supramolecular heterosynthon between
the functional groups, X···Y;

(v)

# Homo = No. of hits that form the supramolecular homosynthon, X···X;
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(vi)

# Pro-synthon = No. of hits that form the supramolecular homosynthon Y···Y;

(vii)

Hetero exclusive = No. of hits that form the supramolecular heterosynthon
between the functional groups, X···Y, in the absence of other functional
groups;

(viii) Range (Å) = H-bond cut off between X and Y supramolecular heterosynthon;
(ix)

Mean (Å, σ) = Average H-bond distance for the X···Y supramolecular hetero
synthon with estimated standard deviation for the H-bond distance;

(x)

Cocrystals = No. of cocrystals which are sustained by the X···Y
supramolecular heterosynthon.

1.6

Discussion:

The statistics obtained from the CSD mining listed in Tables 1.1 to 1.5 represent the
frequency of a particular supramolecular synthon occurring between two functional
moieties along with the range and the mean of H-bond distance. There are around 11,000
hits that contain a carboxylic acid moiety. From the Table 1.1 of all the supramolecular
synthons the frequency of occurrence of COOH∙∙∙Narom heterosynthon is highest when
compared to other synthons. The refined search reveals that the COOH∙∙∙Cl
supramolecular heterosynthon is 100% and the COOH∙∙∙Narom supramolecular
heterosynthon occurs at ca. 92%. The percentage of occurrence of a hydrogen between
COOH and 1o amide functionality is ca. 90% while the O-H∙∙∙C=O supramolecular
synthon is 82%. From the CSD statistics it was also found that when a raw search was
conducted for COOH and 1o sulfonamide moieties, the acid homosynthon dimer was
found to occur at ca. 50% of the time. From a search containing COOH and CN
moieties, the COOH∙∙∙Narom was found to occur at ca. 48% of the time even in the
9

presence of other functional groups. Interactions between a COOH and water molecules
were also analyzed using the CSD. The statistics reveal that in the refined search the
probability of formation of C=O∙∙∙O-H supramolecular heterosynthon between acid
functionality and water molecule was found to be 82%. Of the total 11,000 hits for
carboxylic acids there are about ca. 670 cocrystals exhibit the robust COOH∙∙∙Narom
supramolecular heterosynthon.

Altogether, from the Table 1.1 it is clear that the

functionalities such as Narom, amides (1o), Cl- and carbonyls stand out as complimentary
functionalities to CO, amenable to supramolecular heterosynthon formation.
Table 1.2 represents the CSD statistics obtained for the supramolecular
interactions between O-H (phenolic) with other functionalities. There are about 11,500
hits containing a phenolic moiety indicating the pervasive nature of this function group
amongst organic compounds From the refined searches it was found that phenolic O-H
has a higher tendency to form a heterosynthon with a carbonyl functionality (100%)
within the H-bond range from 2.53-2.96 Å. Similarly, the percentage of forming an Hbond between O-H and a carboxylate was also found to be 100%. The other
functionalities which formed supramolecular heterosynthons at higher percentages are 1o
amine (90%), Cl- (88%), cyano (86%), Narom (82%) and 1o amide (76%). Interestingly,
there is only around 58% of a chance for the formation of O-H∙∙∙O-H between phenols
and water molecules.

From the CSD analysis it is therefore clear that phenolic

compounds hold a potential to be used as a cocrystal former for general purposes as they
are capable of forming supramolecular heterosynthons with various functionalities.
The third category which includes the interactions between 1o sulfonamide and
other functionalities is tabulated in Table 1.3. Around 130 of 231 hits (56%) containing

10

the 1o sulfonamide functionality were either drugs or hits possessing biological activity.
Interestingly, there were very few entries that contained the 1o sulfonamide moiety and
one additional moeity. For example, there were only 4 hits which contain a 1o
sulfonamide and Cl- functionality three of which exhibited the N-H∙∙∙Cl supramolecular
heterosynthon (75%). Similarly, there was just one hit containing the 1o sulfonamide with
the carboxylic acid functionality that exhibited the N-H∙∙∙C=O heterosynthon (100%).
Nevertheless, when a raw search of 1o sulfonamide with other functionalities was
conducted the supramolecular heterosynthons had a much greater percentage of
occurrences. There are only three hits containing a 1o sulfonamide and a cyano group and
even in the presence of other competing functional moieties all of the entries form the NH∙∙∙CN synthon. Likewise, around 89% of the hits containing 1o sulfonamide and Clfunctionality interact via N-H∙∙∙Cl- supramolecular heterosynthon whereas with
functionalities such as esters, Narom and amines the frequency of forming a H-bond with
1o sulfonamide are 63%, 55% and 51%, respectively.
A CSD analysis for 2o sulfonamide with different functionalities is presented in
the Table 1.4. There are around 1,700 hits that contain the 2o sulfonamide functionality
and, similar to that of 1o sulfonamide, the number of entries that contain various
supramolecular heterosynthons in a refined search are minimal. In a refined search there
is around a 73% chance of formation of a supramolecular heterosynthon between 2o
sulfonamide and an amide. During the analysis it was found that there is just one hit of
2o sulfonamide with 1o amide, Cl- and COO- functionalities respectively and each of the
entry forms a supramolecular heterosynthon with the sulfonamide functionality. But,
from this we cannot conclude that there is a 100% chance for the formation of a
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heterosynthon between 2o sulfonamide and 1o amide, Cl- and COO- respectively. Thus
sometimes due to insufficient data in the CSD for some of the supramolecular
heterosynthons, the persistency cannot be determined. The interactions between a 2o
sulfonamide with 1o and 2o amines occurs at higher frequencies (80% and 89%
respectively) in the presence of other moieties. The other functionalities which exhibit a
ca. 50% chance for the formation of supramolecular heterosynthon with 2o sulfonamide
are 2o amide (61%), Narom (56%) and carbonyl groups (45%).
The CSD analysis for PhNHR reveals that there are about 3818 hits, of which
10% hits are either drugs or have biological activity. From Table 1.5 it is evident that
supramolecular heterosynthons occur at a higher frequency in a refined search when
compared to that of a raw search. The functional moieties which are capable of forming a
hydrogen bond with PhNHR at a frequency greater than 50% are Cl- (67%), amide
(62%), carbonyl (59%), phenolic O-H (56%) and cyano (53%). The CSD data also
revealed that the number of cocrystals containing the PhNHR moiety is very low when
compared to other moieties. The statistics obtained from the CSD could in turn be
utilized in designing a crystal engineering experiment for the synthesis of multicomponent crystals.
1.7

Summary

Cocrystals represent novel materials with many practical applications and are one of the
important outcomes of crystal engineering.

The rational design and synthesis of

cocrystals can be pursued with a systematic study by selecting appropriate cocrystal
former based on the persistency of supramolecular synthons that both of the components
are capable of forming. The CSD stands out as a priceless and invaluable tool which
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provides enormous information pertaining to the crystal structure analysis. The CSD data
table enlisted represents how frequently the supramolecular synthon occurs between two
functionalities within the specific range of H-bond distance. Furthermore, the information
could also be utilized for the selection of appropriate cocrystal formers for the synthesis
of cocrystals. The later chapters of this dissertation emphasize the exploration of new but,
robust and persistent supramolecular synthons in the context of crystal engineering of
cocrystals.
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CHAPTER 2
Hierarchy of supramolecular synthons: persistent hydrogen bonds between
carboxylates and weakly acidic hydroxyl moieties in cocrystals of zwitterions
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CHAPTER 3
Hierarchy of Supramolecular Synthons: Supramolecular Homosynthons vs.
Supramolecular Heterosynthons in Cocrystals of Catechols

3.1

Introduction
Cocrystals, a long known1,2 which were relatively little studied until last decade,

are of topical interest because active pharmaceutical ingredients, APIs, are predisposed to
form cocrystals with pharmaceutically acceptable cocrystal formers such as carboxylic
acids. The fact that pharmaceutical cocrystals can profoundly impact clinically important
properties of APIs such as aqueous solubility and crystal form stability justifies the
continued study of pharmaceutical cocrystals.

However, the driving force for the

formation of pharmaceutical cocrystals is molecular recognition between the cocrystal
formers and as such they represent a class of compound that exemplifies how crystal
engineering3,4,5,6 can exploit supramolecular synthons7 for the design of new solids with
desired physicochemical properties.8

Simply put, if a persistent supramolecular

heterosynthon between different but complementary functional groups occurs in favor of
a competing supramolecular homosynthon between identical functional groups, then a
cocrystal can be anticipated for a particular pair of cocrystal formers.9 In such a context,
supramolecular heterosynthons such as acid-pyridine,10 acid-amide,11,12 hydroxylamine,13 hydroxyl-pyridine,13(b),15(e),14,15 aminopyridinium-carboxylate,16 carboxylatehydroxyl (weakly acidic)17 represent persistent supramolecular heterosynthons of the type
26

that can be reliably and readily exploited to prepare new classes of multi-component
solid.

They also provide broad and fundamental insight into molecular recognition

processes.
In such a context, the Cambridge Structural Database (CSD)18 is a powerful tool
that can provide information concerning the reliability and robustness of supramolecular
synthons but only if there are sufficient entries for a given class of compound. The CSD
can thereby afford hierarchal information about the relative strengths of competing
supramolecular synthons, including the hierarchy of supramolecular heterosynthons vs.
any supramolecular homosynthons that might occur between the cocrystal formers. In
addition, there are cocrystals reported in the literature where the target compounds are
sustained by supramolecular homosynthons also in the presence of cocrystal formers.
Cocrystals between two components containing same functionalities have also been
designed and have been explored in carboxylic acid functionalities.
The carboxylic acid dimers formed between two different carboxylic acids have
been referred to as heterodimers and as such they date at least as far back as a study by
Kendall in 1914.19 The Kendall study indicated that cocrystals will form between two
carboxylic acids if their acidic strengths are sufficiently different. Later studies by Pinkus
et al20 suggested that the substituents on the carboxylic acids also have an impact on the
formation of heterodimers. According to this the carboxylic acids containing electronwithdrawing groups are capable of forming heterodimers with systems containing
electron-donating groups. Etter used heterodimers to effect solid-state nucleophilic
substitution in cocrystals formed between two carboxylic acids (4-chloro-3, nitrobenzoic
acid and 4-aminobenzoic acid)21 and most recently Seaton et al22,23 used the Hammett
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substituent parameter (σ) to predict whether or not a cocrystal would result between the
two different carboxylic acids. But, how common is the formation of supramolecular
homosynthon when the components of a cocrystal have different moieties.
To address this issue we investigated the cocrystals of target compounds (inhouse) that contain a catechol moiety (two adjacent O-H functionalities on a benzene
ring). The study would investigate how common is the catechol dimer during the
cocrystal formation and how homosynthon competes with other heterosynthons. Figure
3.1 represents the targeted catechols and the cocrystal formers studied herein. The
phenolic O-H moiety is amphiprotic in nature i.e. it can simultaneously act as a proton
acceptor as well as a donor and it is therefore self-complementary. Furthermore, the pKa
value of an unsubstituted phenol is ca. 10, which means that is unlikely to be
deprotonated even by stronger organic bases. It is therefore possible that phenols could
be more generally used as cocrystal formers than carboxylic acids.

Figure 3.1 Structures of targeted catechols (top two rows) and the cocrystal formers (bottom row).
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We have previously addressed the hierarchy of phenols related to their utility as cocrystal
formers17 and herein we focus upon catechol moieties as a model for nutraceutical
cocrystal formers. Similarly, polyphenols including flavonoids which have attracted the
attention of the scientific community are now also being recognized by the general public
because of their life saving anti-oxidants. Moreover, these polyphenols are widely present
in fruits, vegetables and beverages such as tea, coffee and wine. The availability of plenty
of hydrogen bond donors/acceptors with many utilitarian values including health benefits
suggests that polyphenols and flavonoids are worth studying from a crystal engineering
perspective.
3.2

Experimental:

Nutraceutical compounds such as polyphenols and phenolic acids (Figure 3.1) were
targeted for the present study: caffeic acid (CFA), ethyl gallate (EGL), methyl gallate
(MGL), propyl gallate (PGL) and protocatechuic acid (PCA). Compounds such as: 3, 5
dimethyl pyrazole (DMP), glycine anhydride (GAH), iso-nicotinamide (INM), isoniazid
(INZ) and nicotinamide (NAM) were used as cocrystal formers. All reagents were
obtained from commercial suppliers and used without further purification.
3.2.1

Preparation of single crystals: Single crystals of 11 catechol cocrystals were

obtained by dissolving the starting materials in appropriate solvent(s) followed by slow
evaporation. All solvents were distilled prior to their use. Specific experimental details
are as follows:
Caffeic acid•Glycine anhydride, CFAGAH: Caffeic acid, 18.0 mg (0.100 mmol) and
glycine anhydride, 57.0 mg (0.500 mmol) were dissolved in 3 mL of 1:1 acetone/water
mixture and heated until a clear solution was obtained. The solution was allowed to
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evaporate at room temperature and colorless crystals of CFAGAH were harvested after
two days (melting point = 221.7 oC).
Caffeic acid•Isoniazid, CFAINZ: Caffeic acid, 18.0 mg (0.099 mmol) and isoniazid,
28.0 mg (0.204 mmol) were mixed in 3 mL of 1:1 acetone/water mixture. The resulting
solution was left for slow evaporation in the hood. Light yellow crystals of CFAINZ were
harvested after three days (melting point = 185 oC).
Caffeic acid•Isonicotinamide dihydrate, CFAINM•2H2O: Caffeic acid, 9 mg (0.100
mmol) and isonicotinamide,

30 mg (0.500 mmol) were dissolved in 3 mL of 1:1

methanol/water mixture by heating on a hotplate. The resulting solution was placed in the
hood for slow evaporation. Yellow needle-like crystals were harvested after five days
(melting point = 150.7 oC).
Ethyl gallate•Glycine anhydride, EGLGAH: Ethyl gallate, 20.0 mg (0.101 mmol) and
glycine anhydride, 12.00 mg (0.105 mmol) were mixed in 3 mL of 1:1 ethanol/water
mixture. The resulting solution was left for slow evaporation in the hood. Crystals of
EGLGAH were obtained after a week (melting point = 164.9 oC).
Ethyl gallate•Isoniazid, EGLINZ: Ethyl gallate, 20.0 mg (0.101 mmol) and isoniazid,
14.00 mg (0.102 mmol) were mixed in 3 mL of 1:1 acetone/water mixture. The resulting
solution was left for slow evaporation in the hood. Colorless crystals of EGLINZ were
harvested after two days (melting point = 94.0 oC).
Ethyl gallate•3, 4 dimethyl pyrazole, EGLDMP: Ethyl gallate, 71.28 mg (0.359 mmol)
and 3, 5-dimethylpyrazole, 35.40 mg (0.368 mmol) were mixed in 3 mL of 1:1
ethanol/water mixture. The resulting solution was left for slow evaporation in the hood
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which resulted in colorless crystals of EGLDMP after four days (melting point = 141.4
o

C).

Methyl gallate•Glycine anhydride, MGLGAH: Methyl gallate, 18.0 mg (0.098 mmol)
and glycine anhydride, 12.0 mg (0.105 mmol) were mixed in 3 mL of 1:1 ethanol/water
mixture. The resulting solution was left for slow evaporation in the hood. Crystals of
MGLGAH were harvested after two days (melting point = 227.6 oC).
Methyl gallate•Isoniazid, MGLINZ: Methyl gallate, 18.0 mg (0.098 mmol) and
isoniazid, 14.00 mg (0.102 mmol) were mixed in 3 mL of 1:1 acetone/water mixture.
The resulting solution was left for slow evaporation in the hood. Colorless crystals were
harvested after five days (melting point = 194.3 oC).
Protocatechuic acid•Glycine anhydride, PCAGAH: Protocatechuic acid, 15.00 mg
(0.097 mmol) and glycine anhydride, 12.00 mg (0.105 mmol) were mixed in 3 mL of 1:1
acetone/water mixture. The resulting solution was left for slow evaporation in the hood.
Colorless crystals of PCAGAH were harvested after a week (melting point = 249.9 oC).
Propyl gallate•3, 4 dimethyl pyrazole, PGLDMP: Propyl gallate, 21.0 mg (0.098
mmol) and 3, 5-dimethylpyrazole, 19.0 mg (0.198 mmol) were mixed in 3 mL of
methanol. The resulting solution was left for slow evaporation in the hood. Block like
crystals of PGLDMP were harvested after three days (melting point = 130.8 oC).
Propyl gallate•Glycine anhydride, PGLGAH•2H2O: Propyl gallate, 21.0 mg (0.098
mmol) and glycine anhydride, 24.0 mg (0.210 mmol) were mixed in 3 mL of
ethanol/water mixture. The resulting solution was left for slow evaporation in the hood.
Block like crystals of PGLGAH•2H2O were harvested after three days (melting point =
150.2 oC).
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3.3

Characterization of cocrystals:

3.3.1

Differential scanning calorimetry (DSC): Thermal analysis was performed on a

TA Instruments DSC 2920 Differential Scanning Calorimeter. Aluminum pans were used
for all samples and the instrument was calibrated using an indium standard. For
reference, an empty pan sealed in the same way as the sample was used. The samples
were heated in the DSC cell using inert nitrogen conditions, from 30 °C to the required
temperature (melting point of the cocrystal) at a rate of 10°C/min.
3.3.2

Thermogravimetric analysis (TGA): A Perkin Elmer STA 6000 Simultaneous

Thermal Analyzer was used to conduct thermogravimetric analysis. Open alumina
crucibles were used to heat the samples from 30 °C to 400 °C at 10 °C/min scanning rate
under nitrogen stream.
3.3.3

Infrared spectroscopy (FT-IR): To characterize the cocrystals by infrared

spectroscopy a Nicolet Avatar 320 FT-IR instrument was used. Sample amounts of 1-2
mg were used and spectra were measured over the range of 4000–400cm-1 and analyzed
using EZ Omnic software.
3.3.4

Powder X-ray diffraction (PXRD): A Bruker AXS D8 powder diffractometer

was used for all PXRD measurements with experimental parameters as follows: Cu Kα
radiation (λ = 1.54056 Ǻ); 40 kV and 30 mA. Scanning interval: 3-40° 2θ; time per step:
0.5 sec. The experimental PXRD patterns and calculated PXRD patterns from single
crystal structures were compared to confirm the composition of bulk materials.
3.3.5

Single-Crystal X-ray Data Collection and Structure Determinations: Crystals

suitable for X-ray crystallography were selected using an optical microscope. Data for
CFAGAH, CFAINZ, CFAINM•2H2O, EGLGAH, EGLINZ•2H2O, EGLDMP,
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MGLGAH, MGLINZ, PCAGAH, PGLDMP and PGLGAH•2H2O were collected on
Bruker-AXS SMART APEXII CCD diffractometer with monochromatized Cu Kα
radiation (λ = 1.54178 Å) connected to a KRYO-FLEX low temperature device. Indexing
was performed using SMART V5.625

24(a)

or using APEX 2008 V1-0.34(b) Frames were

integrated with Saint Plus 7.5134(c) software package. Absorption correction was
performed by multi-scan method implemented in SADABS.34(d) The structures were
solved using SHELXS-97 and refined using SHELXL-97 contained in SHELXTL
V6.1034(e) and WinGX V1.70.0134(f,g,h) programs packages. All non-hydrogen atoms were
refined anisotropically. Hydrogen atoms were placed in geometrically calculated
positions or found in the Fourier difference map and included in the refinement process
using riding model or without constraints. Crystallographic data and selected H-bond
distances for the 15 cocrystals are presented in Tables 3.4 and 3.5.
3.4

CSD analysis:

In order to determine the occurrence of catechol supramolecular homosynthons for
compounds containing catechol moiety a CSD v5.32 (Aug 2011 update) study was
conducted. Since O-H moieties of the catechol could act as both acceptor as well as donor
(amphiprotic) the O-H could lead to multiple interactions between themselves and with
other functionalities. Therefore, it is important to understand the possible interactions that
could take place among the catechols. Figure 3.3 represents the possible interactions that
could occur between catechol moieties. The statistical data obtained from the CSD is
tabulated in Table 3.1. All CSD searches were subjected to the following constraints: 3D
coordinates present, only organics, no ions, and R ≤ 7.5% (entries containing salts, metals
and duplicates are excluded).
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Figure 3.2 Histograms of OH•••OH catechol supramolecular homosynthon search obtained from
CSD. (CSD v5.32, Sep 2011 update)

The histogram generated from the CSD search determines the bond distance range for the
occurrence of O-H∙∙∙O-H supramolecular homosynthon as shown in Figure 3.2. The cutoff ranges for the H-bond distances were determined by checking the structures and by
analyzing the H-bond distances. The catechol moieties can interact with each other and
lead to the formation of supramolecular homosynthon I, namely, catechol dimer or
sometimes it may result in the formation of catemer between two catechol moieties,
supramolecular synthon II. Supramolecular synthon III could occur between catechols
when water is present in the crystal structure as represented in Figure 3.3. The hydrogen
distances obtained from the histogram reveal that the supramolecular homosynthons I
and II occur within the typical range of 2.685 – 3.02 Å (mean-2.818 (7) Å).
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Figure 3.3 Possible supramolecular synthons that could occur between catechols.

The raw statistics obtained from the CSD reveal the presence of 460 crystal structures
that contain a catechol moiety.

Of which 97 (22%) entries are sustained by

supramolecular homosynthon I (catechol dimer) whereas 145 (32%) hits are sustained by
supramolecular synthon II. Hydrates are also present among the catechols and are
observed in almost one-fourth of the total catechols. The supramolecular synthon III in
which there are two water molecules inserted in the catechol dimer is exhibited by less
than 5% of the total hits and 26% with supramolecular synthon IV where only one of the
O-H functionality of the catechol moiety interacts with the water molecule. But when
compared within catechol hydrates (Table 3.1), the frequency of supramolecular synthon
IV is observed in almost 94% of hydrates. So far 62 cocrystals (24 cocrystal hydrates)
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have been reported in the CSD that contain the catechol moiety of which only eight
cocrystals (13%) are sustained by catechol dimer.
Table 3.1: CSD statistics for Catechols.
Raw Search:
Total no. of hits with Catechol moiety

440

No. of hits that form supramolecular synthon I (Catechol dimer)

97 / 440 (22.0%)

No. of hits that form supramolecular synthon II

145 / 440 (31.5%)

No. of hits that form supramolecular synthon III

19 / 440 (4.3%)

No. of hits that form supramolecular synthon IV

113 / 440 (25.7%)

No. of hits with Catechol + nH2O

120 / 440 (27.3%)

No. of hits that form supramolecular synthon I (among catechol hydrates)

10 / 120 (8.3%)

No. of hits that form supramolecular synthon II

24 / 120 (20%)

No. of hits that form supramolecular synthon III

19 / 120 (15.8%)

No. of hits that form supramolecular synthon IV

113 / 120 (94.2%)

No. of cocrystals that have Catechol moiety

62 / 440 (14.1%)

No. of cocrystals that form supramolecular synthon I

8 / 62 (12.9%)

No. of hits that form supramolecular synthon II

11 / 62 (17.7%)

No. of cocrystals that have Catechol moiety + nH 2O

24 / 64 (37.8%)

No. of hits that form supramolecular synthon III

1 / 24 (4.2%)

No. of hits that form supramolecular synthon IV

23 / 24 (95.8%)

Refined Search:
Total no. of hits with Catechol moiety

13

No. of hits that form supramolecular synthon I

8 (61.5%)

No. of hits that form supramolecular synthon II (some hits also contain synthon I)

8 (61.5%)

Constraints: Only organics, no ions, 3D coordinates, R ≤ 0.075, no duplicates

Supramolecular synthons II, III and IV are exhibited by 18%, 2% and 37% respectively
and in rest of the cocrystals the O-H moieties of the polyphenols are bonded to other
functional groups. The refined search contains only thirteen entries containing catechol
moiety where 62% of the crystal structures were found to contain supramolecular
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synthons I and II. There is just one cocrystal, NEZMAG25 (1,1-bis(4-Hydroxyphenyl)
cyclohexane and catechol), in the refined search (no other functional groups than O-H
moiety) which is sustained by a tetramer formed by two of each catechol (only one of the
O-H) and 1,1-bis(4-Hydroxyphenyl) molecules.
3.5.

Description of the crystal structures

3.5.1

CFAINM•2H2O: The cocrystallization of CFA and INM resulted in the

formation of a dihydrate of the cocrystal. The CFA molecules are disordered in the
cocrystal. A catechol dimer (supramolecular homosynthon-I) was not observed in the
CFA molecules but instead there is an insertion of four water molecules between the two
CFA molecules preventing them from forming the dimer. The insertion of water
molecules results in 3+3 hexameric unit. The acid moiety of CFA molecule donates a
hydrogen bond to the Narom moiety of INM molecule resulting the robust COOH···Narom
hydrogen bond (2.733 (1) Å). The amide moieties if the INM molecules engage
themselves in formation of amide dimer with hydrogen bond distance between N-H···O
equal to 2.941 (2) Å. The interactions between the CFA, water and the INM molecules
thereby results in the generation of a linear tape and these tapes are sandwiched by
adjacent tapes.

Figure 3.4 Illustration of intermolecular hydrogen bonding in CFAINM•2H 2O (The CAF molecules
are disordered in the cocrystal).
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Each tape interacts with the adjacent tapes through: (a) the O-H of the acid moiety of
CFA molecules with one water molecule; (b) the anti-hydrogen of the amide functionality
INM the molecules hydrogen bond to the carbonyl moiety of CFA molecules
respectively. The hydrogen bond distances observed for O-H···O and N-H···O
interactions are 2.830 (3) Å and 3.005 (2) Å respectively. Overall hydrogen bonding is
illustrated in Figure 3.4.
3.5.2

CFAINZ: The CFAINZ cocrystal crystallizes in centro-symmetric space group

(P-1) with one molecule of CFA and INZ in the asymmetric unit. The cocrystal is
sustained by the supramolecular synthon I (Figure 3.5). The hydrogen bond distance
between O∙∙∙O-H for the supramolecular synthon I is 2.753(2) Å which falls within the
range generated by the histogram for O-H···O-H interactions.

Figure 3.5 Illustration of supramolecular sheet generated by the intermolecular interactions in
CFAINZ.

The INZ molecules hydrogen bond to the catechol dimer peripherally with the antihydrogens of the hydroxyl moieties (O···O: 2.671() Å, O···N: 2.976 () Å). Whereas the
acid moiety of CFA molecules hydrogen bond to the Narom of the INZ molecules through
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the robust supramolecular heterosynthon O···Narom (O…N: 2.618 () Å) thereby resulting
in the formation of linear tapes. The O···Narom supramolecular heterosynthon formed
between the CFA and INZ molecules follows the hierarchy for the intermolecular
interactions between the carboxylic acids and Narom.23(b) The tapes in CFAINZ are linked
to each other laterally through the interactions between the carbonyl of CFA and the antihydrogens of the hydrazine moieties (O···N (2.886() Å) leading to the formation of a
supramolecular sheet as represented in Figure 3.5.
3.5.3

CFAGAH: The 1:1 cocrystal of CFAGAH did not contain any of the synthons as

proposed in Scheme 1 rather the cocrystal is stabilized by the tapes of GAH dimers
(O···N: 2.892 (2), 2.916 (2) Å). The supramolecular homosynthon (dimers) formed
between the amide functionalities of two GAH molecules can be represented by graph set
notation26

(8). Similar kinds of dimers are also observed in the pure crystal structure

of GAH with hydrogen bond distance of 2.84 Å. The tapes of GAH dimers hydrogen
bond to one of the O-H and the acid moieties of the CFA molecules on either side
through O···O-H: 2.722 (2) Å and O···O-H: 2.650 (1) Å) respectively.

(a)
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(b)

Figure 3.6 (a) Representation of hydrogen bonding in CFAGAH; (b) CFA dimer as observed in
CFAGAH.

The other O-H and the carbonyl moieties of CFA molecules engage themselves in the
formation of dimers as represented in Figure 3.6 (b) but, this kind of dimer formation is
not observed in the pure crystals structure of CFA molecules. Whereas, the CFA
molecules are exist as acid dimers and the interactions between the O-H moieties. Overall
hydrogen bonding is shown in Figure 3.6 (a). Twelve cocrystals of GAH have been
reported to date in the CSD of which five cocrystals are sustained by GAH dimers as
observed in CFAGAH.
3.5.4

EGLDMP: The cocrystallization of EGL and DMP resulted in the formation of a

1:1 cocrystal in centro-symmetric space group (P-1) with one molecule of each in the
asymmetric unit. In EGLDMP the catechol moieties of EGL molecules interact with
each other through supramolecular homosynthon I with hydrogen bond distance of 2.654
(2) Å which can be described by

(10) graph set as shown in Figure 3.7 (a). Two DMP

molecules hydrogen bond on either side of synthon I via O-H···N and O···N-H hydrogen
bonds (O-H···N: 2.705 (2) Å; O···N: 2.832 (2) Å) thereby generating a supramolecular
sheet. Thus the overall hydrogen bonding results in the generation of sheets in the form of
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bilayers which stack in ABAB fashion stabilized by weak π-π interactions as represented
in Figure 3.7 (b). The EGL molecule in the cocrystal is observed to be flat with all the OH moieties lying on the plane.

(a)

(b)
Figure 3.7 (a) Generation of supramolecular sheet in EGLDMP; (b) Stacking of bilayers in ABAB
fashion.

The only cocrystal of EGL reported in the CSD (PIJHIA)27 with 2-(6-diethylamino-3diethyliminio-3Hxanthene- 9-yl) benzoate (rhodamine B base-RBB) is sustained by
charge assisted 2-point hydrogen bond (COO-···O-H ) between the carboxylate and the
O-H moieties. One of the O-H moieties of the EGL molecule in the cocrystals is out of
the plane by 67.82o whereas in EGLDMP all the O-H moieties are planar.
41

3.5.5

EGLGAH: The 2:1 EGLGAH cocrystal is sustained by supramolecular synthon

I via O-H∙∙∙O hydrogen bond (2.707 () Å and 2.705 () Å) with two of the O-H moieties of
the EGL molecule involved in the dimer formation. The intermolecular hydrogen bond
distances of the supramolecular I are within anticipated range obtained from the CSD
(2.685 – 2.968 Å).

Figure 3.8 Intermolecular hydrogen bonding in EGLGAH.

The GAH dimer no longer exists in the cocrystal as they did in CFAGAH. The amide
moiety of GAH molecules laterally connect the catechol dimers through O-H∙∙∙O (2.678
() Å) and O-H∙∙∙N-H (2.950 () Å) H-bonds thereby generating a linear tape. These tapes
are connected to the adjacent tapes through EGL dimers described by

(14) graph set

as illustrated in Figure 3.8 and results in the formation of corrugated sheet. The dimer is
formed between the O-H and C=O moieties of two EGL molecules via O-H∙∙∙O (2.739 ()
Å and 2.738 () Å) hydrogen bonds. The EGL molecule in the cocrystal is not planar
whereas the dihedral angle between the aliphatic chain and the gallate ring is 79.64o. The
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supramolecular corrugated sheets form layers stacked one above the other as presented in
Figure 3.9.

Figure 3.9 Illustration of stacking of supramolecular layers.

3.5.6

EGLINZ•2H2O: The cocrystallization of EGL and INZ result in the formation of

the dihydrate of the cocrystal. There are three EGL, two INZ and two water molecules in
the asymmetric unit. Synthon III is observed rather than synthon I in the cocrystal with
the unexpected presence of water in the crystal structure. The serendipitous formation of
the dihydrate illustrates the unpredictable nature of water in crystal engineering
experiments.28 One of the water is trifurcated between other two EGL molecules through
O-H∙∙∙O hydrogen bonds (2.719 () Å, 2.969 () Å, 2.972 () Å) and connect the O-H
moieties of two EGL molecules whereas the other water molecules connects the N-H
moiety of the INZ and the O-H moiety of the remaining EGL molecule through N-H∙∙∙O
(2.837 () Å) and O-H∙∙∙O (2.726 () Å) hydrogen bond. The O-H moieties of these two
EGL molecules hydrogen bond to the Narom of the INZ molecules thus forming the robust
O-H∙∙∙Narom (2.69 () Å, 2.632 () Å) supramolecular heterosynthon.14(b) The overall
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hydrogen bonding results in the formation of a supramolecular sheet, represented in
Figure 3.10. Unlike in EGLGAH, the EGL molecules in EGLINZ•2H2O are planar in
the cocrystal.

Figure 3.10 Hydrogen bonding in EGLINZ•2H2O.

3.5.7

MGLGAH: The cocrystallization between MGL and GAH results in the

formation of 2:1 molecular complex in monoclinic space group (C2/c). The MGLGAH
cocrystal is also sustained by supramolecular synthon I with the hydrogen bond distance
between O-H∙∙∙O of 2.720 (2) Å

Figure 3.11 Illustration of twisted catechol dimer in MGLGAH.
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. The catechol dimer unlike in other cocrystals is not planar and is twisted by a dihedral
angle of 53.23o as presented in Figure 3.11. In all the GAH cocrystals (which are
sustained by catechol dimers) discussed so far, GAH forms a tetrameric unit by hydrogen
bonding itself on the either side of the catechol dimer but in MGLGAH it is not so.
Instead, each the N-H moieties of the GAH molecules forms bifurcated hydrogen bonds
with two hydroxyl moieties of two different MGL molecules thereby connecting two
catechol dimers. The N-H∙∙∙O hydrogen bond distances are 2.999 (2) Å and 3.060 (2) Å
as represented in Figure 3.12 (a).

(a)

(b)
Figure 3.12 Hydrogen bonding environment around GAH molecules (a) involving N-H moiety (b)
involving C=O moiety in MGLGAH.
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Similarly the carbonyl moieties of GAH molecules are also hydrogen bonded to another
catechol dimer via C=O∙∙∙O-H hydrogen bonds (2.688 (2) Å as shown if Figure 3.12 (b).
The overall hydrogen bonding in MGLGAH results in the formation of a 3-D network as
shown in Figure 3.13.

Figure 3.13 Overall hydrogen bonding in MGLGAH.

3.5.8

MGLINZ: The crystals structure of MGLINZ reveals the presence of two

independent MGL and one INZ molecules in the asymmetric unit. Supramolecular
homosynthon I is present in the cocrystal in which one of the independent MGL molecule
participates in the dimer formation. The hydrogen bond distances observed for the
catechol dimer in MGLINZ are 2.915 (3) Å (O-H∙∙∙O). The hydrazine moieties INZ
molecules hydrogen bond to the peripherals of the catechol dimer via N-H∙∙∙O (2.680 (3)
Å and 2.953 (3) Å) hydrogen bonds similar to that found in the cocrystals CFAINZ and
GALINZ (reported elsewhere). The second independent MGL molecule interacts with
INZ and other independent MGL molecules by donating two hydrogen bonds to Narom
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(O-H∙∙∙Narom) and the carbonyl moieties (O-H∙∙∙O) and the hydrogen bonds for these
interactions are 2.661 (3) Å and 2.689 (3) Å respectively. Overall crystal packing in
MGLINZ is presented in Figure 3.14.

Figure 3.14 Crystal packing of 2:1 MGLINZ cocrystal.

3.5.9

PCAGAH: The 1:1 complex between PCA and GAH does not exhibit any of the

supramolecular synthons mentioned in scheme 1. The supramolecular homosynthons
sustained by GAH dominates the other hydrogen bonds in the crystal structure. The
hydrogen bond distances for the GAH dimers (N-H∙∙∙O: 2.941 (2) Å) are greater than
what is observed in the pure crystal structure of GAH (N-H∙∙∙O: 2.851 Å). Through out
the crystal structure of PCAGAH the GAH molecules exists as dimers which are
connected to other dimers via C=O∙∙∙N-H (2.947 (2) Å) hydrogen bonds. The one of the
carbonyl moieties of GAH molecule forms a bi-furcated hydrogen bond with one of the
O-H moieties of thePCA molecules generating a tape as presented in Figure 3.15 (a). The
remaining O-H of each PCA molecule donates a hydrogen bond to the carbonyl moiety
(O-H∙∙∙C=O: 2.721 (2) Å) of the acid group of neighboring PCA molecule as shown in
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Figure 3.15 (b) (GAH molecules are removed for clarity) thus generating anti-parallel
tapes of PCA molecules.

(a)

(b)

(c)
Figure 3.15 (a) Illustration of tape generated by the H-bonding between PCA and GAH molecules;
(b) Interactions occurring between PCA molecules; (c) Interactions occurring between GAH
molecules.

Likewise the GAH molecules hydrogen bond to other GAH molecules to form dimers
with a hydrogen bond distance of 2.941 (2) Å and these dimers are connected to other
dimers via N-H∙∙∙C=O bonds (2.947 (2) Å) as represented in Figure 3.15 (c). The
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hydrogen bond distance observed is greater than what is observed in pure GAH crystal
structure (PCA molecules are not shown for clarity). The overall hydrogen bonding
results in the formation of 3-D network as illustrated in Figure 3.16.

Figure 3.16 Illustration 3-D network resulted in PCAGAH cocrystal viewed along x-axis.

3.5.10 PGLDMP: The crystal structure of PGLDMP reveals that the PGL and DMP
molecules form a 1:1 complex. The cocrystal is sustained supramolecular homosynthon I
through strong O-H∙∙∙O (2.664 (2) Å) hydrogen bonds. The DMP molecules hydrogen
bond to the catechol dimer (Figure 3.17) through Narom∙∙∙O-H and N-H∙∙∙O hydrogen
bonds (2.689 (2) Å and 2.818 (2) Å) similar to that observed in cocrystals EGLDMP and
GALDMP32. The molecular assembly which is formed between two each of PGL and
DMP molecules interacts with four neighboring assemblies. The interactions take place
between third O-H of the PGL and the carbonyl moieties (O-H∙∙∙O: 2.687 (2) Å) of PGL
molecules as presented in Figure 3.18. The tetrameric assemblies are found to be planar
in EGL and PGL whereas in GALDMP, the DMP molecules are out of plane containing
the catechol dimer with a dihedral angle of 44.51o.
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Figure 3.17 Illustration of catechol supramolecular homosynthon (synthon-I) in PGLDMP.

Figure 3.18 Interactions of the molecular assemblies formed in PGLDMP.

3.5.11 PGLGAH•2H2O: The cocrystal crystallizes in monoclinic space group (P21/c)
with the asymmetric unit consisting of two independent PGL molecules, two water
molecules and one GAH molecules. The supramolecular synthon I was expected in the
cocrystal but due to the unexpected intrusion of water molecules in the crystal structure
neither of the GAH dimers were observed. Each of the PGL molecule donates bi-furcated
hydrogen bonds to the GAH molecule via O-H∙∙∙N-H (2.640 (2) Å) and O-H∙∙∙O (2.993
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(2) Å) interactions. Likewise bifurcated bonds are formed by each water molecule with
two of the O-H moieties of PGL molecules (O∙∙∙O-H: 2.781 (2) Å and 2.960 (2) Å)
resulting in the formation of supramolecular synthon IV (Figure 3.19).

Figure 3.19 Asymmetric unit of PGLGAH•2H2O.

The remaining O-H and the carbonyl moieties of the PGL molecules interact with GAH
and water molecules respectively (not shown in the figure). The hydrogen bond distances
observed for these interactions are 2.725 (2) Å and 2.885 (3) Å. The overall hydrogen
bonding generates 2-D network as presented in Figure 3.20.

Figure 3.20 Overall hydrogen bonding in PGLGAH•2H2O.
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3.6

Discussion:

Of all the catechol cocrystals considered for this study, 11 are reported herein and six
(CFANAM•H2O, GALADN, GALDMP, GALINZ, GALGAH and QUEINM,) have
been reported elsewhere.25,26,32 Out of 17 cocrystals,

15 of them are sustained by

supramolecular homosynthons (12 are sustained by the catechol dimer and three are
sustained by amide dimer). The two cocrystals which were not sustained by any
supramolecular homosynthon are EGLINZ•2H2O and PGLGAH•2H2O. Even though
CFANAM•H2O and CFAINM•2H2O were also hydrates they exhibit catechol and
amide dimers respectively. In this context the cocrystals of carbamazepine (CBZ),29,30,31
one of the most studied pharmaceutical cocrystals, are more appropriate examples which
exhibit supramolecular homosynthon (amide dimer) during the cocrystal formation. Of
all the reported 34 cocrystals of CBZ, 18 cocrystals are sustained by amide dimer (CBZ)
where the CCFs hydrogen bond to the peripherals of the dimer. Figure 3.21 illustrates the
CBZ-saccharin (UNEZAO) and CBZ-nicotinamide (UNEZES) cocrystals where the
cocrystal is sustained by the amide dimer of CBZ whereas the CCF molecules H-bond to
the dimer on the peripherals.

(a)
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(b)
Figure 3.21: (a) CBZ-Saccharin cocrystal; (b) CBZ-Nicotinamide cocrystal.

The relative strength of supramolecular homosynthon exhibited by amides is greater
when compared to carboxylic acids, alcoholic O-H and phenolic O-H functionalities as
demonstrated by Infantes et al.32 According to their report, the relative strength of the
supramolecular homosynthons is amides > acids > alcohols. Their study revealed that the
carboxylic acid supramolecular homosynthons can be overcome in the presence of other
functional groups whereas the amide dimers are relatively strong. But, in the present
study the cocrystals EGLGAH and MGLGAH were sustained by catechol dimer even in
the presence of GAH molecule which is capable of forming the amide dimer as in
CFAGAH and PCAGAH. This could be attributed to the erratic nature of catechols
which brings in a huge diversity in terms of supramolecular synthons as exemplified by
the cocrystals reported in here.
In order to compare the frequency of occurrence of the catechol dimer, the
hydrogen bonding in the cocrystals have been compared to the individual polyphenols
including their corresponding hydrates. Among the seven catechols (present study), only
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MGL exist in the anhydrous form with the crystal structure reported in the CSD (Table
2.3) whereas, CFA, EGL and PGL exist only as hydrates. GAL and PCA exist in both
hydrate and anhydrous forms with reported crystal structures. The anhydrous form of
GAL exhibit supramolecular synthon II and its four (3rd and 4th forms has been reported
by Clarke et al)33 polymorphic monohydrates exhibit supramolecular synthons I, II and
IV emphasizing the promiscuity of water leading to various hydrogen bonds satisfying
the donor-acceptor ratios. PCA exhibit the catechol dimer in its anhydrous form whereas,
its hydrate exhibit supramolecular synthons II and IV. No other polyphenol has been
found to exhibit supramolecular synthon I in anhydrous or hydrate form.
Table 3.2 Supramolecular homo and heterosynthons observed in the cocrystals.
Supramolecular synthon

Cocrystals

Synthon-I
(O-H∙∙∙O-H)

CFANAM•H2O, CFAINZ, EGLDMP, EGLGAH, GALADN,
GALDMP, GALGAH, GALINZ, MGLGAH, MGLINZ, PGLDMP,
QUEINM (12)

Synthon-II
Synthon-III
(O-H∙∙∙water∙∙∙O-H)
Synthon-IV
(O-H∙∙∙water)
O-H∙∙∙C=O
Amide dimer
Acid dimer
Acid-Amide dimer
COOH∙∙∙Narom
O-H∙∙∙Narom

CFANAM•H2O, EGLINZ•2H2O (2)
CFAINM•2H2O, EHLINZ•2H2O, PGLGAH•2H2O (3)
CFAINZ, CFAGAH, EGLDMP, EGLGAH, MGLGAH, MGLINZ,
PCAGAH, PGLDMP, PGLGAH•2H2O, QUEINM (10)
CFAINM•2H2O, CFAGAH, PCAGAH (3)
CFANAM•H2O (1)
CFAINM•2H2O, CFAINZ (2)
EGLDMP, EGLINZ•2H2O, GALADN, MGLINZ, PGLDMP,
QUEINM (5)

*The number in the parenthesis represents the total no. of cocrystals exhibiting the synthon.

This observation suggests that the catechol dimer is not very prominent in single
component systems (catechols alone) whereas in multicomponent systems such as
cocrystals, the dimer is more frequently observed. Therefore, it could be possible that the
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cocrystallization is capable of yielding the catechol dimer. Of all the cocrystal hydrates
containing catechol moiety (reported in the present study as well as in the CSD) only one
cocrystal CFANAM•H2O exhibited the catechol dimer. This observation implies that the
presence of water molecules more than likely prevents the formation of the catechol
dimer.

Apart from the supramolecular synthons listed in scheme I, various other

synthons are also exhibited (Table 3.2) by the cocrystals. The O-H∙∙∙C=O supramolecular
heterosynthon also occurred equally with catechol dimer indicating the reliability of the
synthon between hydroxyls and the carbonyl compounds.
Table 3.3 List of catechols and their corresponding hydrates with CSD ref codes and the
supramolecular synthon exhibited by them.

Polyphenol

CSD ref code

Supramolecular
synthon exhibited

CSD ref code of the
corresponding
hydrate(s)

Supramolecular
synthon
exhibited

CFA

No structure
reported

NA

FESNOG34

II, IV

36

IV
I, IV
I, IV

GAL

MGL
EGL
PGL
PCA
QUE

IJUMEG35
39

ROMGAC
No structure
reported
No structure
reported
WUYNUA41
No structure
reported

II

KONTIQ
KONTIQ0137
Form III35
Form IV35
(KONTIQ03)38
No hydrates reported

NA

No hydrates reported

NA

NA

FACVAH40

IV

II

BIJDON04

I
NA

II, IV
NA

43

II, IV

42

III

FEFBEX01

Amide dimers are also exhibited by cocrystals CFAINM•2H2O, CFAGAH, and
PCAGAH•2H2O even in the presence of other functional groups such as carboxylic acid
and Narom functionalities. Of the six cocrystals (CFAINM•2H2O, CFANAM•H2O,
CFAGAH, CFAINZ, GALADN, GALGAH, GALDMP, GALINZ and PCAGAH)
that contain a carboxylic acid moieties none of them exhibited the acid dimer. This
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establishes the fact that supramolecular heterosynthons are more prominent than
supramolecular homosynthons. The robust COOH∙∙∙Narom and O-H∙∙∙Narom supramolecular
heterosynthons are also observed in some of the cocrystals.
3.7

Conclusions:

Most of the nutraceuticals with catechol moieties are rich in antioxidant properties are
relevant in the pharmaceutical industries either as dietary supplements or as excipients
which have been understudied in the context of crystal engineering. Some of the phenolic
acids used in the present study are suitable candidates as potential CCFs. The present
study demonstrates that the O-H∙∙∙O-H (catechol dimer) supramolecular homosynthon
does not resist the formation of cocrystals in catechols. From Table 3.3 it is evident that
most of the catechols do not have the crystal structure reported in the CSD and thus it is
difficult to conclude that whether the catechol dimer is persistent in single component
systems or multi component systems. Nevertheless it is observed in the present study that
the supramolecular homosynthons and heterosynthons occur almost at the same
frequency in catechol cocrystals. Even though supramolecular heterosynthons are
considered to be the key factor in sustaining a cocrystal, supramolecular homosynthons
are equally dominant in catechols cocrystals. However, the CSD does not contain enough
data for cocrystals that contain catechols to evaluate the reliability of the catechol dimer
in catechols cocrystals. It is evident from the absence of adequate data from the CSD that
this class of compounds is relatively less explored in the context of cocrystals, thus
offering an opportunity to study and understand the supramolecular chemistry of
catechols.
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Table 3.4 Crystallographic data and structure refinement parameters for the cocrystals.
CFAGAH

CFAINM•
2H2O

CFAINZ

EGLDMP

EGLGAH

Formula

C13H14N2O6

C15H18N2O7

C15H15N3O5

C14H18N2O5

C22H26N2O12

MW

294.26

338.31

317.30

294.30

510.45

904.83

Crystal system

Triclinic

Triclinic

Triclinic

Triclinic

Triclinic

Triclinic

Space group

P-1

P-1

P-1

P-1

P-1

P-1

a (Å)

6.1600 (3)

8.5694(1)

7.4163 (3)

7.4755 (2)

11.7057 (2)

9.3112(2)

b (Å)

8.0178 (4)

9.4912(2)

9.7537 (3)

9.7262 (3)

12.5290 (3)

14.4155(3)

c (Å)

13.4643 (6)

9.5505(2)

10.3709 (4)

10.9370 (3)

13.0113 (3)

17.2588(3)

 (deg)

90.271 (3)

93.312(1)

74.085 (2)

97.051 (2)

115.285 (1)

108.323(1)

 (deg)

101.790 (3)

91.537(1)

84.020 (2)

94.327 (2)

93.711 (1)

101.024(1)

 (deg)

96.325 (3)

99.397(1)

78.768 (2)

109.148 (2)

106.499 (1)

99.991(1)

646.75 (5)

764.56(2)

706.59 (5)

739.83 (4)

1615.85 (6)

2089.60 (7)

1.511

1.470

1.491

1.321

1.574

1.438

V /Å

3

Dc/mg m-3

EGLINZ•
2H2O
C39H48N6O1
9

Z

2

2

2

2

3

2

2 range

3.35 to 65.52

4.64 to 65.97

4.44 to 62.33

4.10 to 65.48

3.85 to 67.44

2.80 to
66.57

Nref./Npara.

2135 /201

2534/350

2183/232

2409/196

5379/500

6920/650

T /K

225 (2)

100 (2)

100 (2)

293 (2)

100 (2)

100 (2)

R1 [I>2sigma(I)]

0.0347

0.0365

0.0594

0.0459

0.0419

0.0474

wR2

0.0900

0.0975

0.1553

0.1241

0.1071

0.1185

GOF

1.028

1.057

0.962

1.043

0.992

1.030

Abs coef.

1.035

1.003

1.021

0.848

1.112

0.991

MGLGAH

MGLINZ

PCAGAH

PGLDMP

PGLGAH•
2H2O

Formula

C20 H22 N2O12

C22H23N3O11

C11H12N2O6

C15H20N2O5

C24H34N2O14

MW

482.40

505.43

268.23

308.33

574.53

Crystal system

Monoclinic

Monoclinic

Monoclinic

Monoclinic

Monoclinic

Space group

C2/c

P21/c

P21/n

P21/n

P21/c

a (Å)

26.1861 (7)

10.3058(5)

8.0640 (3)

7.7170 (2)

15.6501(3)

b (Å)

3.7362 (1)

11.8783(5)

6.4791 (2)

8.8082 (2)

4.80800(10)
17.4557(3)

c (Å)

20.7953 (6)

17.7690(6)

22.3446 (6)

23.1797 (4)

 (deg)

90

90

90

90

90

 (deg)

108.232 (1)

94.857(3)

97.610 (2)

99.042 (1)

100.9240(10)

 (deg)

90

90

90

90

90

3

1932.40 (9)

2167.39 (16)

1157.17 (6)

1556.01 (6)

1289.67 (4)

Dc/g cm-3

1.658

1.549

1.540

1.316

1.480

Z

4

4

4

4

2

2 range

3.55 to 65.80

4.31 to 63.01

3.99 to 66.45

3.86 to 67.68

5.16 to 67.29

Nref./Npara.

1609/158

3206 /333

1971/184

2693/211

2251/206

V /Å

T /K

100 (2)

100(2)

100 (2)

100 (2)

100(2)

R1 [I>2sigma(I)]

0.0354

0.0460

0.0392

0.0419

0.0422

wR2

0.0946

0.1092

0.1064

0.0995

0.1070

GOF

1.068

1.023

1.099

1.044

1.052

Abs coef.

1.202

1.081

1.095

0.830

1.027
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Table 3.5 Selected hydrogen bond distances and parameters for the cocrystals reported herein.
D
(D∙∙∙A)/Å
2.700 (2)
2.722 (2)
2.651 (1)
2.917 (2)
2.892 (2)
2.838 (6)
2.687 (1)
2.854 (1)

θ /º

H-Bond

O-H···O
O-H···O
O-H···O
N-H···O
N-H···O
O-H···O
O-H···O
O-H···O

d (H•••A)
/Å
1.89
1.97
1.84
2.00
1.99
1.95 (3)
1.80 (3)
2.02 (3)

D (D∙∙∙A)/Å

θ /º

O-H···O
O-H···O
O-H···O
N-H···O
N-H···O
O-H···O
O-H···O
O-H···O

d (H•••A)
/Å
1.96 (3)
2.36(3)
1.84 (4)
2.27 (3)
2.36 (3)
1.86
1.94
2.32

165.2
150.8
167.2
177 (2)
167 (2)
172(2)
175(2)
161(2)

2.780 (2)
2.738 (2)
2.639 (2)
3.112 (3)
2.947 (3)
2.688 (2)
2.720 (2)
2.755 (2)

165 (3)
108 (2)
157 (4)
153 (3)
141 (3)
170.6
153.5
112.6

N-H···O

2.08 (3)

2.935 (2)

163.2(2)

N-H···O

2.01 (2)

N-H···O

2.19

3.060 (2)

168.0

2.9201(2)

174.6(2)

O-H···N

1.89

2.661 (3)

O-H···O

152.3

2.07 (4)

2.748(3)

131 (3)

O-H···O

2.21

2.915 (3)

141.0

O-H···O
N-H···O
N-H···O
N-H···O

2.14 (4)
2.32 (3)
2.48 (3)
2.50 (3)

2.739 (3)
3.148 (3)
2.977 (3)
3.329(3)

123 (3)
145 (3)
112 (2)
146 (3)

O-H···O
N-H···O
N-H···O
O-H···O

1.86
2.16
2.38
1.79

2.680 (3)
2.953 (3)
3.118 (3)
2.620 (2)

166.9
149.2
142.1
169.0

O-H···O
O-H···O
O-H···O
O-H···O
N-H···O
N-H···O
N-H···O
O-H···O
O-H···O
O-H···O
O-H···N
O-H···O
O-H···O
N-H···O
N-H···O

2.01
2.28
1.92
1.90
2.10
2.01
2.48
1.91
2.00
2.27
1.879 (2)
1.91 (4)
1.79 (4)
2.31 (2)
2.38 (2)

2.654 (2)
2.714 (2)
2.705 (2)
2.720 (2)
2.832 (2)
2.950 (2)
3.108 (2)
2.739 (2)
2.694 (2)
2.711 (2)
2.756 (3)
2.778(2)
2.631 (2)
3.191 (3)
3.143 (3)

135.2
113.5
158.7
177.7
142.2
165.5
122.5
169.0
139.5
113.2
170 (3)
171(3)
160 (4)
166 (3)
145 (3)

O-H···O
O-H···O
N-H···O
N-H···O
N-H···O
O-H···O
O-H···O
O-H···O
O-H···O
N-H···O
O-H···O
O-H···O
O-H···O
N-H···O
N-H···O

1.89
1.91
2.05 (2)
2.05
2.19
1.85
1.97
226
1.88
2.01 (2)
1.89
1.91
1.79
2.05 (2)
2.60 (2)

2.721 (2)
2.572 (2)
2.941 (2)
2.941 (2)
2.947 (2)
2.687 (2)
2.664 (2)
2.710 (2)
2.689 (2)
2.818 (2)
2.721 (2)
2.572 (2)
2.620 (2)
2.941 (2)
3.174 (2)

169.0
135.0
171 (2)
171 (2)
147 (2)
172.1
138.9
113.6
161.3
146.9
169.0
135.0
169.0
171 (2)
122 (2)

H-Bond

CFAGAH

CFAINM•
2H2O

CFAINZ

EGLDMP

EGLGAH

EGLINZ•
2H2O

3.8

PGLGAH•
2H2O

MGLGAH

MGLINZ

PCAGAH

PGLDMP

PCAGAH
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CHAPTER 4
Crystal Engineering of p-Coumaric acid: Synthesis and solubility studies of
cocrystals
4.1

Introduction

Nature has an immense reserve of the finest examples of supramolecular architectures
sustained by molecular self-assemblies which are governed by non-covalent interactions.
Inspired by these examples crystal engineering emerged as an important tool in
supramolecular chemistry which aids in the invention of new molecular structures with
desired properties. Thus, the primary motto of crystal engineering could be stated as
“making crystals with purpose”. The new molecules are designed through supramolecular
synthons and yet not limited to robust synthons which gives room for new
supramolecular synthons to be discovered. Pharmaceutical cocrystals are one of the
important outcomes of crystal engineering which furnish opportunities for the active
pharmaceutical ingredients (APIs) to fine-tune their properties. Current literature is
loaded with plenty of examples where the physico-chemical and pharmacokinetic
properties such as solubility, dissolution rate, stability and bioavailability have been
greatly modified via cocrystallization.
Nutraceuticals, whose legal position on the legislative grounds is marginal
between pharmaceutics and food1, offer a wide array of molecules which are worth
studying due to: a) health benefits associated with them; b) limited solubilities and bioavailabilities; c) availability of amphiprotic functionalities such as O-H suitable for Hbonding.

The term nutraceutical was coined by Stephen De Felice in 1976.2
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Nutraceuticals are widely distributed in nature.3 They exhibit many biologically
significant functions, such as protection against oxidative stress, degenerative diseases
and are best known for their anti-oxidative properties.4 Because of these characteristic
properties of nutraceuticals we focused our research on the crystal engineering of
nutraceuticals.5 As a part of this, our work deals with the crystal engineering of
hydroxycinnamic acids namely p-coumaric acid (COU), caffeic acid (CFA) and ferulic
acid (FER) that includes the synthesis, characterization, and the study of their properties.
The cocrystals of CFA and FER have been reported elsewhere.6 The study also focuses
on how the substituents on the hydroxycinnamic acid have an effect on the crystal
packing and the aqueous solubilities of the cocrystals.
COU is a nutraceutical which is one of the most abundant hydroxy derivatives of
cinnamic acid (Figure 4.1). It is found in a wide variety of edible plants such as peanuts,
tomatoes, carrots, apples, pears, grapes, beans, spinach leaves and garlic7 including
beverages such as coffee, tea, wine, chocolate, beer and in olive oil.8 It is readily
absorbed from the gastrointestinal tract via the monocarboxylic acid transporter.9 COU is
a nutraceutical17,10 which has antioxidant properties that protects against low-density
lipoprotein (LDL) and is believed to reduce the risk of stomach cancer 11 by reducing the
formation of carcinogenic nitrosamines.12 A study conducted by Zang et al revealed that
COU effectively scavenges •OH in a dose-dependent manner.15(c) In various studies
conducted by different groups, COU helped in reducing the plasma cholesterol levels15(c)
and found to possesses anti-inflammatory properties,13 a weak antileukemic activity14 and
goitrogenic activity.15
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Figure 4.1 Structure of COU.

The primary focus of the present study is crystal engineering of multicomponent crystals
of COU and to investigate (a) the effect of cocrystallization on its solubility and (b) the
correlation of solubility and melting point (MP) between the CCF and the cocrystal. So
far five cocrystals of COU have been reported in the Cambridge Structural Database
(CSD) with caffeine (1:1 and 1:2), theophylline (two polymorphic cocrystals, Forms I
and II) and 2,3,5,6-tetramethylpyrazine.16,17 A third polymorph of COU cocrystal with
THP is reported in the present report.
4.2

Selection of CCFs for COU based on CSD analysis

The functional groups that are present in COU are carboxylic acid and hydroxyl
(phenolic) and understanding the supramolecular chemistry of these functionalities aids
in the selection of appropriate CCFs. Carboxylic acids can behave as both acceptor and a
donor which form complementary hydrogen bonds and tend to exist as dimers. The
statistics obtained from the CSD reveal 30.1% of the total structures (9362 total
structures) are sustained by acid dimers in the presence of other competing functional
groups and 76% in the absence of other competing groups. Phenols are less acidic than
carboxylic acids but more acidic than aliphatic alcohols. The weak acidic nature of
phenol can be attributed to the stable phenoxide ion that is formed after the loss of proton
due to resonance. From the archived literature and the statistics obtained from the CSD,
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certain functional groups such as Narom are obvious to form hydrogen bonds with
carboxylic acids and phenols. In this context, Shattock et al has extensively studied the
hierarchy of supramolecular synthons between carboxylic acids and hydroxyls with basic
Narom.18 Their study revealed 98% occurrence of the COOH…Narom supramolecular
heterosynthon and 78% occurrence of the OH…Narom supramolecular heterosynthon in the
absence of other competing functionalities. The basic nitrogen has a higher probability of
breaking the supramolecular homosynthon (acid dimer) among the carboxylic acids and
form a robust COOH…Narom at a greater percentage. Figure 4.2 represents the most
probable interactions among acids, amides, phenols and Narom functionalities.

OH

O

O

HN

OH

N

O

H
II

I

OH

N

III
Figure 4.2 (i) Acid-amide supramolecular heterosynthon; (ii) COOH…Narom supramolecular
heterosynthon; (iii) OH…Narom supramolecular heterosynthon.

Similar searches for the occurrence of supramolecular heterosynthon for carboxylic acids
and phenols with other functionalities such as carbonyls, purines and amides were
conducted in the absence of other competing functionalities. The results from the
searches revealed that amides have 82 and 80% of chances of hydrogen bonding with
phenols and carboxylic acids respectively. Likewise, there is 55% chance of occurrence
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of hydrogen bonding between carboxylic acids and phenols.

The supramolecular

heterosynthons of carboxylic acids with functional groups such as carbonyls and phenols
occur at 39.9 and 33.3% respectively. Thus, CSD is a valuable tool in selection of
appropriate CCFs for the target molecules based on the statistical analysis. The crystal
structure of COU (Ref code: COUMAC01) reported in the CSD reveals that the COU molecules
form acid dimers and O-H···O-H hydrogen bonds.19 Therefore, in order to make the cocrystals of
COU these supramolecular homosynthons have to be overcome. In a supramolecular point of
view COU has carboxylic acid and phenolic hydroxyl moieties that could act as acceptors and
donors as well. The evidence from the CSD statistics and the literature reveal that carboxylic acid
and hydroxyl functional groups exhibit a variety of hydrogen bonding motifs and perceivably to
some extent one can predict supramolecular heterosynthons that involve these two groups even in
the presence of other competing functional groups.18

4.3

Experimental Section

To synthesize cocrystals of COU, the CCFs nicotinamide (NAM), isonicotinamide
(INM), isonicotinic acid (INA), isoniazid (INZ), urea (URE), theophylline (THP),
theobromine (TBR), betaine (BTN) listed in Figure 4.3 are used
CONH2
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N

N

N
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Figure 4.3 Structures of cocrystal formers with the three letter code.
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. All reagents were obtained from commercial suppliers and used without further
purification. All solvents were distilled prior to their use.
4.3.1

Preparation of cocrystals via solvent-drop grinding20: Stoichiometric amounts

of starting materials were ground for five minutes in the presence of solvents such as
methanol, DMF, water (10 μL of per 50 mg of starting material) or in the absence of
solvent (neat grinding) using an agate mortar and pestle. The resulting powders were
characterized by powder X-ray diffraction (PXRD), differential scanning calorimetry
(DSC) and Fourier transform infra-red spectroscopy (FT-IR).
4.3.2

Preparation of cocrystals via slurrying: Stoichiometric amounts of starting

materials were slurried overnight (1 mL of water, per 500 mg of starting material). The
undissolved solid is isolated by filtration and characterized using PXRD, DSC and FT-IR.
4.3.4

Preparation of single crystals: Single crystals for the cocrystals are obtained by

dissolving the starting materials in appropriate solvent(s) followed by slow evaporation.
All reagents were obtained from commercial suppliers and used as such without further
purification. Specific details are as follows:
Coumaric acid • Nicotinamide, COUNAM: COU, 228.1mg (1.380 mmol) and NAM,
170.2 mg (1.390 mmol) were mixed in 2 mL of ethanol and slurried overnight. The
resulting solution was filtered by using a filter paper. The resulting filtrate was left for
slow evaporation in the hood and the precipitate was analyzed by powder x-ray
diffraction. Colorless crystals of COUNAM were harvested after three days (MP =
159°C).
Coumaric acid • Isonicotinamide, COUINM-I (1:1): COU, 228.1mg (1.380 mmol) and
INM, 170.2 mg (1.390 mmol) were mixed in 2 mL of ethanol and slurried overnight. The
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resulting solution was filtered by using a filter paper. The resulting filtrate was left for
slow evaporation in the hood and the precipitate was analyzed by powder x-ray
diffraction. Colorless crystals of COUINM-I were harvested after two days (MP =
172°C).
Coumaric acid • Isonicotinamide, COUINM-II (1:2): COU, 16.7 mg (0.100 mmol) and
INM, 30.0 mg (0.500 mmol) were dissolved in 3 mL of ethyl acetate by heating on a
hotplate. The resulting solution was left for slow evaporation in the hood Colorless
crystals of COUINM-II were harvested after four days (MP = 165.5°C).
Coumaric acid • Theophylline, COUTHP : COU, 16.4 mg (0.100 mmol) and THP
anhydrous, 18.0 mg (0.100 mmol) were mixed in 3 mL of ethanol and the resulting
solution was left for slow evaporation in the hood. After two days colorless needles of
COUTHP were obtained (melting point = 223.4°C).
Coumaric acid • Theobromine dihydrate, COUTHB•2H2O: COU, 16.4 mg, (0.100
mmol) and TBR, 17.0 mg (0.100 mmol) were mixed in 3 mL of 1:1 ethanol/water
mixture. The resulting solution was left for slow evaporation in the hood. Colorless
crystals of COUTBR•2H2O were harvested after five days (MP = 228.04°C).
Coumaric acid • Theobromine, COUTBR: COU, 16.4 mg, (0.100 mmol) and TBR,
17.0 mg (0.100 mmol) were mixed in 3 mL of 1:1 ethanol/water mixture. The resulting
solution was left for slow evaporation in the hood. Colorless crystals of COUTBR•2H2O
were harvested after five days which transform to COUTBR (anhydrate form) with in
less than 24 h (MP = 228.04°C).
Coumaric acid • Isoniazid, COUINZ: COU, 16.41 mg (0.1000 mmol) and INZ, 13.71
mg (0.1000 mmol) were dissolved in 3 mL of ethanol by heating on a hotplate. The
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resulting solution was placed in the hood for slow evaporation. Yellow plate like crystals
of COUINZ were harvested the next day (MP = 178°C).
Coumaric acid • Urea, COUURE: COU, 16.41 mg (0.1000mmol) was dissolved to a
saturated solution of URE, (≥ 98% pure used as received from Sigma Aldrich) in ethanol.
The resulting solution was heated on a hotplate and was left at room temperature for slow
evaporation. Colorless needles of COUURE were harvested after six days (MP
=123.5oC).
Coumaric acid • Betaine, COUBTN: COU, 1.641 g (0.010mol) and BTN, 4.684 g
(0.020mol) were added to 3 mL of water and slurried for two days. The resultant mixture
was left for slow evaporation. Colorless crystals of COUBTN are obtained after a week.
(MP =170.9 oC).
Coumaric acid • Iso-nicotinic acid, COUINA: COU, 1.641 g (0.010mol) and INA, 1.23
g (0.010mol) were added to 3mL of water and slurried overnight. The resultant yellow
colored powder was left for drying and is analyzed by PXRD, DSC and TGA to confirm
the formation of cocrystal. The crystal structure of COUINA is obtained from the PXRD
pattern. (MP =217.8 oC).
4.4

Characterization of Cocrystals

4.4.1

Differential scanning calorimetry (DSC): Thermal analysis was performed on a

TA Instruments DSC 2920 Differential Scanning Calorimeter. Aluminum pans were used
for all samples and the instrument was calibrated using an indium standard. For
reference, an empty pan sealed in the same way as the sample was used. Using inert
nitrogen conditions, the samples were heated in the DSC cell from 30°C to the melting
point of the cocrystal at a rate of 10°C/min. Table 2 lists the melting points of the all the
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cocrystals obtained by DSC and the melting points of the starting materials obtained from
the literature.
4.4.2

Thermogravimetric analysis (TGA): A Perkin Elmer STA 6000 Simultaneous

Thermal Analyzer was used to conduct thermogravimetric analysis. Open alumina
crucibles were used to heat the samples from 30°C to the required temperature at 10
°C/min scanning rate under nitrogen stream.
4.4.3

Infrared spectroscopy (FT-IR): Characterization of the cocrystals by infrared

spectroscopy was accomplished with a Nicolet Avatar 320 FT-IR instrument. Sample
amounts of 1-2 mg were used and spectra were measured over the range of 4000 –
400cm-1 and analyzed using EZ Omnic software.
4.4.4

Ultraviolet/Visible Spectroscopy (UV/Vis): UV/vis analysis was performed on a

Perkin-Elmer Lambda 900 UV/vis/NIR spectrometer for dissolution studies.
4.4.5

Powder X-ray diffraction (PXRD): A Bruker AXS D8 X-ray powder

diffractometer was used for all PXRD measurements with experimental parameters as
follows: Cu Kα radiation (λ = 1.54056 Ǻ); 40 kV and 30 mA; Detector type: Scintillation
type; Scanning interval: 3-40° 2θ; time per step: 0.5 sec. The experimental and calculated
PXRD patterns from single crystal structures were compared to confirm the composition
of bulk materials.
4.4.6

Single-Crystal X-ray Data Collection and Structure Determination: Crystals

suitable for X-ray crystallography were selected using an optical microscope. Data for the
cocrystals were collected on Bruker-AXS SMART APEXII CCD diffractometer with
monochromatized Cu Kα radiation (λ = 1.54178 Å) connected to a KRYO-FLEX low
temperature device. Indexing was performed using SMART V5.625
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21(a)

or using APEX

2008 V1-0.21(b) Frames were integrated with Saint Plus 7.5121(c) software package.
Absorption correction was performed by multi-scan method implemented in
SADABS.21(d) The structures were solved using SHELXS-97 and refined using SHELXL97 contained in SHELXTL V6.1021(e) and WinGX V1.70.0121(f,g,h) programs packages.
All non-hydrogen atoms were refined anisotropically.
Table 4.1 Crystallographic data and structure refinement parameters for the cocrystals
COUNAM

COUINM-I

COUINM-II

COUTBR

COUTBR•2H2O

Formula
MW
Crystal system
Space group
a (Å)
b (Å)
c (Å)
 (deg)
 (deg)
 (deg)
V /Å3
Dc/mg m-3
Z
2 range
Nref./Npara.
T /K
R1 [I>2sigma(I)]
wR2
GOF
Abs coef.

C15 H14N2O4
286.28
Monoclinic
P21/c
15.5635 (5)
6.3162 (2)
14.1472 (5)
90
106.043 (2)
90
1336.54 (8)
1.423
4
5.92 to 67.80
2366/214
100 (2)
0.0361
0.0903
1.040
0.874

C15 H14N2O4
286.28
Triclinic
P-1
6.9663 (3)
7.3890 (5)
14.6499 (7)
91.135 (4)
99.602 (3)
118.103 (3)
651.65 ( 6)
1.459
2
3.08 to 66.77
2165/197
100 (2)
0.0408
0.1034
1.017
0.896

C21 H20 N4 O5
408.41
Monoclinic
P21
3.9360 (4)
10.3970 (8)
23.6212 (2)
90
93.486 (7)
90
964.85(14)
1.406
2
1.87 to 67.05
3126/275
293 (2)
0.0443
0.1109
1.037
0.853

C16 H16 N4 O5
344.33
Triclinic
P-1
8.8549 (2)
9.0831 (2)
11.2492 (3)
79.674 (2)
69.785 (2)
67.328 (2)
782.32 (3)
1.462
2
4.19 to 67.21
2615/275
293 (2)
0.0423
0.1070
1.014
0.936

C16H20N4O7
380.36
Monoclinic
P21/c
15.3236 (4)
8.8959 (2)
12.9598 (4)
90
102.781 (2)
90
1722.87 (8)
1.466
4
2.96 to 67.38
3033/313
100 (2)
0.0362
0.0911
1.024
0.992

COUINZ

COUURE

COUBTN

COUTHP-III

Formula
MW
Crystal system
Space group
a (Å)
b (Å)
c (Å)
 (deg)
 (deg)
 (deg)
V /Å3
Dc/g cm-3
Z
2 range
Nref./Npara.
T /K
R1 [I>2sigma(I)]
wR2
GOF
Abs coef.

C20H20N4O5.33
401.73
Monoclinic
P21/n
7.3854 (2)
5.7039 (1)
32.6563 (6)
90
92.776 (1)
90
1374.05 (5)
1.456
4
5.42 to 68.37
2359/260
100 (2)
0.0343
0.0978
1.011
0.900

C20H20N4O5.33
224
Monoclinic
C2/c
16.0219 (3)
6.11800 (10)
19.9780 (3)
90
110.9110 (10)
90
1829.3
1.410
4
4.74 to 67.38
1592/142
100 (2)
0.0326
0.0814
0.978
0.917

C14 H15 N3 O3
273.29
Triclinic
P-1
6.4229 (5)
8.9868 (8)
12.6875 (11)
100.371 (4)
92.031(5)
99.829 (5)
708.14 (10)
1.282
2
3.55 to 66.10
2362/193
293 (2)
0.0548
0.1287
1.000
0.762

C16H16N4O5
344.33
Triclinic
P-1
6.8266 (6)
8.7088 (8)
26.843 (2)
90.138 (7)
92.366 (7)
99.901 (8)
1570.7 (2)
1.456
4
3.30 to 65.08
5052/463
225 (2)
0.0690
0.1593
1.009
0.932
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Hydrogen atoms were placed in geometrically calculated positions or found in the Fourier
difference map and included in the refinement process using riding model or without
constraints. The crystallographic data for the cocrystals reported herein are presented in
Table 4.1.
4.4.7

Crystal Structure Solution from Powder X-ray Diffraction: The cocrystals

which are crystalline and yet difficult to obtain the single crystals, under such
circumstances the crystal structure can be solved from the powder X-ray diffraction data.
In case of COUINA and COUBTN, the crystal structures were solved using
computational software TOPAS Academic.22,23 PXRD measurements are performed at
beam line X16C of the National Synchrotron Light Source at Brookhaven National
Laboratory. The samples are lightly ground and loaded into a nominal 1.5-mm diameter
glass capillary, which is then flame sealed. X-rays of a particular wavelength are selected
by a Si (111) channel cut monochromator. Diffracted X-rays are selected by a Ge (111)
analyzer and detected by a scintillation counter. The incident intensity is monitored by
an ion chamber and used to normalize the measured signal. Structure solution is
performed by simulated annealing as implemented in TOPAS Academic.
Table 4.2 Crystallographic data and structure refinement parameters for COUINA
COUINA (Data obtained from PXRD data using TOPAS Academic software)
Formula
MW
Crystal system
Space group
a (Å)
b (Å)
c (Å)
 (deg)
 (deg)

C15H13O5N
287.26
Triclinic
P-1
7.41858 (22)
8.93427 (27)
11.36671 (34)
86.9643 (26)
74.2132 (22)
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 (deg)
V /Å3
Dc/g cm-3
Z
2 range
T /K
Rwp
R exp
GOF

66.9010 (20)
665.610 (37)
1.43
2
3.0 to 35.0
300
4.28
2.06
2.08

From this initial solution, the structure is successfully refined with TOPAS Academic.
Table 4.2 represents the crystallographic data obtained from PXRD data using TOPAS
Academic software.
4.5

Synthesis of Cocrystals in Bulk for Dissolution

In order to scale up the synthesis of cocrystals from milligram scale to gram can be
achieved by slurry method. All of COU acid cocrystals were reproduced by slurrying in
water except COUINM-II (slurried in ethyl acetate) and COUTBR (slurried in ethanol).
For each cocrystal stoichiometric amounts of the starting materials (except COUBTN
and COUURE 1:2 ratio were used) in 5-6 mL of solvent are added and stirred overnight
with the help of a magnetic stir bar on a stir plate. Slurrying resulted in 100% conversion
of the starting materials to cocrystal. The purity of the bulk material is tested by PXRD
and DSC. For PXRD the pattern of the bulk material is compared to the PXRD obtained
from the single crystal X-ray diffraction, and the presence of any additional peaks other
than the peaks in the calculated pattern indicates starting materials or impurities.
4.6

Cocrystal Solubility Evaluation: Solubility studies were performed on pure

COU and its cocrystals including the 1:2 cocrystal of COU with caffeine (COUCAF)16
using UV/vis/NIR spectrophotometry in water. The wavelength used for COU was
selected as 315 nm where the interference of the CCF is not observed in the UV
spectrum. A uniform particle size (between 53 and 75 μm) for the bulk powder was
obtained for all the cocrystals and pure COU by sieving. The dissolution studies are
conducted by taking approximately 4 grams of the cocrystal in 70 mL of water and were
stirred with a magnetic stir bar at ca. 125 rpm for 24 hours. Aliquots are drawn from the
slurry at regular time intervals (5, 10, 15, 20, 25, 30, 45, 60, 75, 90, 120, 150, 180, 240
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and 1440 minutes) and filtered using a 0.45 μm nylon filter. The filtrates are diluted
appropriately and analyzed to measure the concentration of COU (at 315 nm) by using
UV/VIS/NIR spectrometer. The remaining solid was analyzed by PXRD and DSC to
confirm the crystal form. The solubility measurements were done in replicates of three.
4.7

Crystal Structure Descriptions

Based on the statistics obtained from CSD for the reliability of supramolecular
heterosynthon involving phenols and carboxylic acid suitable cocrystals formers were
targeted. Herein we report structurally characterized ten cocrystals of COU.
4.7.1

COUNAM:

Anticipating

the

O-H···Narom

/acid···Narom

supramolecular

heterosynthons between COU and NAM the cocrystallization experiment was carried on.
The anticipation was based on supramolecular studies established through various
studies.18 A 1:1 complex was yielded between COU and NAM with four molecules of
each in the unit cell. The crystal structure reveals that p-coumaric acid and nicotinamide
molecules exist as acid-amide dimers (N-H···O: 2.911 (2), O-H···O: 2.541 (2) Å) and
these dimers are connected to other dimers through O-H…Narom (2.705 (2) Å)
supramolecular hydrogen bonds resulting in the formation of a corrugated tape. In the
crystals structure of COUNAM the acid···amide dimers form a cyclic

(8) and a chain

C(4) graph sets24 as illustrated in Figure 4.4. The corrugated tapes are linked through
C(4) chains which are formed by the lateral hydrogen bonding between the acid and the
amide moieties (N-H···O-H: 2.947 (2) Å). The overall hydrogen bonding results in the
formation of a network that could be described as a supramolecular corrugated sheet.
Nine cocrystals of NAM are reported with molecules containing a COOH and O-H
moieties in the CSD. Of the nine cocrystals, five are found to be sustained by
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acid···amide supramolecular heterosynthon and the O-H hydrogen bonds to Narom similar
to that in COUNAM only when water molecule is not present (three cocrystals). In the
hydrate cocrystals of NAM with molecules containing a COOH and O-H moieties the
water molecule interrupts the bond between O-H and Narom. The cocrystals which are
sustained by amide dimer, the acid moiety hydrogen bonds to Narom and the O-H to antihydrogens of the amide functionality.

Figure 4.4 Intermolecular hydrogen bonding in 1:1 COUNAM cocrystal.

4.7.2

COUINM I: Slurrying COU and INM in the presence of ethanol results in the

formation of 1:1 cocrystal, COUINM-I. The cocrystal crystallizes in centrosymmetric
space group, P-1. The cocrystal is also sustained by the complementary acid-amide
dimers (N-H···O: 3.040 (2), O-H···O: 2.586 (2) Å) and these dimers are connected to
other through OH···Narom (2.694 (2) Å) supramolecular hydrogen bonds similar to that in
COUNAM (Figure 4.5). The only difference lies in the lateral hydrogen bonding that
occurs between the tapes in both cocrystals. Unlike COUNAM, the tapes are linear and
form a 2+2 tetramer described by

(8) graph set generating a layer.
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Figure 4.5 Hydrogen bonding in COUINM illustrating the 2+2 tetramer.

The anti-hydrogens of INM molecules hydrogen bond to the carbonyl of acid moieties
(N-H···O: 2.981 (2) Å) of the adjacent tapes resulting in the formation of

(8) graph set

as illustrated in Figure 4.5. The layers generated by the 2+2 tetramers align themselves in
the form of ABCABC as shown in Figures 4.6 (a) and (b) which interacts through weak
C=O···C-H interactions.

(a)

(b)
Figure 4.6 Weak interactions between the layers (ABC) generated by the 2+2 tetramers in COUINMI (a); side view (b).

According to the CSD statistics there are seven cocrystals of INM with CCF containing
COOH and O-H moieties. Of the seven cocrystals, one cocrystal BUFQAU25,30
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(a)

is a

ternary cocrystal where the acid-amide dimer, COOH···Narom and O-H···C=O
supramolecular heterosynthons are observed. Three cocrystals exhibit the amide dimer
along with COOH···Narom O-H···N-H supramolecular heterosynthons. Cocrystal
MUPNER26 exhibits similar kind of 2+2 teteramer (as shown in Fig 4.5) seen in
COUINM-I.
4.7.3

COUINM II: Slow evaporation of COU and INM in 1:5 stoichiometric ratio in

ethyl acetate resulted in 1:2 cocrystal of COUINM-II. Unlike COUINM-I, the
acid…amide dimers are broken. In COUINM-II, two INM molecules interact with one
COU molecule through and the COOH···Narom (2.691 (4) Å) and O-H···Narom (2.691 (4)
Å) supramolecular synthons.

Figure 4.7 Supramolecular sheet generated in COUINM-II.

The amide moieties of INM molecules interact with neighboring INM molecules through
N-H···C=O H-bonds (2.796 (4) Å). Of the two INM molecules that form the 1:2
cocrystal with COU, one of the C=O moiety of the INM molecules does not participate in
the H-bonding. The anti-H atoms of INM molecules interacts with C=O of COU
molecules in the adjacent tapes (2.969 (4) Å). The overall H-bonding results in the
formation of a supramolecular sheet as illustrated in Figure 4.7.
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4.7.4

COUTHP: A third polymorphic cocrystal of COU and THP (Form III, MP:

223.4 oC) has been reported here. Forms I (IJIBEJ, MP: 219.64 oC) and II (IJIBEJ01,
MP: 203.62 oC) are reported elsewhere.16 These forms were produced concomitantly
whereas during the synthesis of COUTHP, Forms I and III are produced concomitantly.
This can be confirmed by the DSC (see supplementary data) which exhibits two
endotherms which corresponds to Form I and III. The crystal structure of COUTHP
reveals that COU acid and THP molecules are sustained by dimers represented by

(9)

graph set. The dimer is formed between the N-H of imidazole ring, C=O of the
pyrimidine ring of THP and the acid moiety of COU molecules

Figure 4.8 Represent the H-bonding in all the three polymorphs of COUTHP. Form II and III with
their cell parameters.
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. The dimers are linked to other dimers via O-H···N (basic) hydrogen bonds resulting in
the formation of undulating tape. Similar kind of dimer is also observed in Forms I and II
(Figure 4.8). Form II forms undulating tapes similar to that in COUTHP (Form III), but
when closely observed the dihedral angle between the planes containing COU-THP
dimers in Form III differs by almost 8 degrees from Form II. Figure 4.9 illustrates the
dihedral angles formed between two COU-THP dimers. When the stoichiometric
amounts of COU and THP are slurried in water for 24 h, Form III is isolated with no
traces of Form I found in the endotherm obtained by DSC (see supplementary data), slow
evaporation produces Form I and III concomitantly.

Figure 4.9 Illustration of dihedral angles subtended by the planes containing COU-THP dimers in
Forms II and III.

4.7.5

COUTBR•2H2O & COUTBR: The CSD statistics reveal that carboxylic acids

are capable of forming cocrystals with xanthines like theobromine, theophylline and
caffeine which led to the isolation of cocrystal between COU and TBR. The
cocrystallization between COU and TBR resulted in the formation of dihydrate of
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COUTBR•2H2O which later transforms to COUTBR eventually. This is example of
single crystal to single crystal transformation where one crystalline form transforms to
the other form. In the crystal structure of the cocrystal, COU and TBR molecules are held
together by an acid-amide dimer (O-H···O: 2.616 (2) Å, N-H···O: 2.847 (2) Å). These
dimers in turn are connected to other dimers through hydrogen bonding between N-H of
the imidazole ring of TBR and O-H of COU molecules via two water molecules as
illustrated in the Figure 4.10 (O-H···N (basic): 2.914 (2) Å, O···O-H: 2.709 (2) Å, O···OH: 2.599 (2) Å). The overall hydrogen bonding results in the formation of zigzag tapes.
The CSD survey for TBR molecule revealed the presence of only two cocrystals
(CSATBR27, MUPPET25), and both of them were synthesized with CCF containing
COOH and O-H moieties. Both the cocrystals are sustained by the acid-imide dimer
which is also observed in COUTBR•2H2O. The O-H moiety in CSATBR is involved in
intramolecular H-bonding with C=O moiety of the acid group whereas in MUPPET the
O-H and N (basic) interactions are interfered by the insertion of water molecules.

Figure 4.10 Ball and stick representation single hydrogen bonded tape in the dihydrate of 1:1
COUTBR.2H2O cocrystal.
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The weight loss at 102.55 oC from the TGA data (see Appendix 18) of COUTBR•2H2O
corresponds to the loss of single water molecule. It is possible that the water molecules
are lost gradually once they are out of the mother liquor. This raises the possibility for
phase transformation of COUTBR•2H2O to a new form. The TGA recorded after 24 h
on the crystals of COUTBR•2H2O showed no water loss which confirms the complete
transformation of COUTBR•2H2O to an anhydrous form namely, COUTBR (see
Appendix 19). So to confirm the identity of the crystals after exposing
COUTBR•2H2O in air for 24 h, a single crystal was picked and the single X-ray
diffraction data was collected. The data obtained from the single X-ray diffraction
confirmed the transformation of COUTBR•2H2O to COUTBR.
The 1:1 cocrystal of COUTBR is held also held together by the acid-amide dimer
similar to that in COUTBR•2H2O.

Since the water molecules are not present in

COUTBR, the O-H moiety of COU interacts with the basic N of the imidazole moiety of
TBR molecule thereby generating linear tapes as presented in Figure 4.11.

Figure 4.11 Intermolecular interactions in COUTBR.
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4.7.6

COUINZ: Continuing attempts for crystal engineering of COU with various

functional groups lead us to target INZ as one of the suitable cocrystal former due to the
presence of Narom and hydrazine moieties. INZ, drug which is used for the treatment
against tuberculosis, is an organic compound which contains a hydrazine and Narom
moieties. The cocrystallization of COU and INZ resulted in 1:1 cocrystal of COUINZ.
The asymmetric unit of COUINZ cocrystal contains one molecule each of COU and
INZ. In the crystal structure COU and INZ molecules exist as acid-hydrazine dimers
described by

(7) graph set (O-H···N: 2.601 (2) Å, O···N-H: 2.887 (2) Å). The dimers

are connected to other adjacent dimers through O-H···Narom (2.736 (2) Å) supramolecular
heterosynthon.

Figure 4.12 Intermolecular hydrogen bonding in the 1:1 COUINZ cocrystal.

The hydrogen bonding in COUINZ results in the formation of corrugated tapes as
illustrated in Figure 4.12. The intermolecular hydrogen bonding between the tapes
through N-H…O hydrogen bond (2.985 (2) Å) result in the formation of C(3) chains as
shown in Figure 4.13 and therefore, the overall network could be described as a
supramolecular corrugated sheet.
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Figure 4.13 Illustration of C(3) chains in COUINZ.

4.7.7

COUURE: COU crystallizes with URE in C2/c space group with 6 formula units

in the unit cell. The acid dimer is exhibited by COU molecules with a hydrogen bond
distance of 2.648 (2) Å. The C=O of the acid functionality of COU interacts with the one
of N-H of each amine moiety of URE through O···N-H hydrogen bond (2.984 (2) Å),
whereas the remaining N-H of URE hydrogen bonds with the O-H moiety of COU (OH···N-H: 2.964 (2) Å). The O-H moiety of COU forms a bifurcated H-bond with the
C=O moiety of URE through O-H∙∙∙C=O hydrogen bond (2.601 (2) Å). There are four
cocrystals of URE with molecules that contain both an acid and O-H moiety and out of
which the acid dimer is observed in only one cocrystal whereas acid-amide dimers were
observed in two of them. In the remaining one, the O-H moiety of the acid group interacts
with the N-H of the URE molecule. Overall hydrogen bonding between COU and URE
leads to the generation of 3-D network as shown in Figure 4.14.
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Figure 4.14: Illustration of 3-D network in COUURE cocrystal.

4.7.8

COUBTN: The structure for this cocrystal (also COUINA) was earlier

determined from the PXRD data as we were unable to obtain the single crystals. More
recently, a slurry of the starting materials in 1:2 stoichiometric ratio in water resulted in
single crystals of COUBTN from which the structure was determined and compared to
that obtained from the PXRD data. The results revealed that both structures are in
agreement with each other. Persistent interactions between carboxylate and acidic O-H
moieties have already been established in one of our recent publications.28 Similar kinds
of interactions are observed in COUBTN cocrystal. COUBTN crystallizes in P-1 space
group where the phenolic O-H of the hydroxyl and the carboxylic acid moieties of COU
interact with carboxylate moiety of BTN molecule (O-H∙∙∙COO- : 2.650 (1), 2.598 (3)).
This hydrogen bonding results in the formation of a tetramer between two of each COU
and BTN molecules as illustrated in Figure 4.15.
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Figure 4.15 Illustration of tetramer formed in COUBTN.

Ten cocrystals of BTN are reported in the CSD, of which five cocrystals are sustained by
COO-···O-H (acidic) interactions. Three cocrystals are sustained by COO -···N-H
supramolecular

heterosynthon

whereas

two

cocrystals

exhibit

COO-···COOH

supramolecular heterosynthon similar to that in COUBTN.
4.7.9

COUINA: According to the structure solution of COUINA from the PXRD

powder pattern (TOPAS Academic software) the cocrystal crystallizes in P-1 space
group. The crystal structure of COUINA reveal that the COU molecules are held by the
acid dimers (O-H∙∙∙O: 2.643 (2)) and the INA molecules form head-to-tail anti-parallel
tapes through strong O-H∙∙∙Narom hydrogen bonds (2.493 (2)) as represented in Figure
4.16. The carbonyl moiety of INA interacts with the O-H of the COU molecules (OH∙∙∙C=O: 2.722 (2)). The COU dimers are sandwiched between the linear anti-parallel
tapes formed by the INA molecules. Overall hydrogen bonding between COU and INA
results in the formation of a supramolecular sheet. However, there is an ambiguity about
the existence of INA molecules in neutral form as there is also a possibility of them to
exist in the zwitterionic form. The existence of the zwitterionic form of INA molecules
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has already been exhibited by some of the our nutraceutical cocrystals reported elsewhere
(CITINA•2H2O, GALINA•H2O, PCAINA•H2O and QUEINA•H2O).26

Figure 4.16 Supramolecular sheet formed between COU and INA molecules as observed in COUINA.

From the PXRD data it is in fact impossible to locate the position of hydrogen in INA
molecule but this doesn’t rule out the possibility of INA molecules to exist in the
zwitterionic form in the cocrystal. Figure 4.17 represents the H-bond distances and the CN-C bond angle of INA molecule in the cocrystal and in the pure form.

Figure 4.17 Comparison of H-bond distances and the C-N-C bond angle in pure INA and in the
cocrystal.
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The C-O & C=O bond distances of INA the cocrystal and in the pure form are 1.304 Å
and 1.226 Å & 1.294 Å and 1.215Å respectively whereas the C-N-C bond angles are
119.99o and 118.91o respectively. In the cocrystal the H-bond between the acid O-H and
the Narom for INA in the cocrystal (O-H∙∙∙Narom: 2.511Å) is much stronger in the cocrystal
when compared to bond distance in the pure form of INA (O-H∙∙∙Narom: 2.592 Å). The CN-C bond angle and the O-H∙∙∙Narom H-bond distance of INA in the cocrystal are
consistent with that of observed in the other cocrystals of INA where it exists as
zwitterion.26 The attempts to obtain the single crystals for COUINA were not successful
so far.
4.8

Discussion

COU is weakly acidic with pKa of 4.32 and could form a salt with appropriate base. The
formation of cocrystals or salts is governed by the rule of thumb according to which a
cocrystals is produced only when the difference in pKa of two compounds is negative
(ΔpKa = pKa base- pKaacid < 0 = cocrystal) and a salt in the other case. The pKa and ΔpKa
values of the CCFs selected for the present study are listed in Table 4.3. The
cocrystallization experiments with selected CCFs resulted in the isolation of ten
cocrystals of COU. Even though the ΔpKa of THP and COU is around 4.5, three
polymorphic cocrystals are formed between the two as opposed to what is anticipated
(salt) whereas the rest of the cocrystals follow the rule of thumb. The robust
supramolecular heterosynthon observed in the cocrystals of COU is O-H···Narom
(COUNAM, COUINM-I, COUINM-II, COUTHB, COUTHP, COUINA and
COUINZ).
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Table 4.3 pKa values of COU and the CCFs29
Compound

pKa

∆pKa = pKa(CCF) – pKa (COU)

NAM
INM
INA
THP
TBR
INZ
URE
BTN

0.5, 3.35
3.67
1.70, 4.89
8.8
0.59, 9.9
1.8, 3.5, 9.5
0.18
1.84

-3.82, -0.97
-0.62
-2.8, 0.39
4.48
-3.73, 5.58
-2.52, -0.82, 5.18
-4.14
-2.48

This demonstrates that the interactions between O-H and Narom follow the hierarchy of
supramolecular strategy established by a study conducted by Shattock et al.18 The
cocrystals COUNAM, COUINM-I, COUTBR, and COUTBR•2H2O are found to be
sustained by acid∙∙∙amide dimer overcoming the acid∙∙∙acid and amide∙∙∙amide
supramolecular homosynthons whereas, the acid dimer in COU remained intact in only
two cocrystals namely COUINA and COUURE. The CSD statistics reveal that acidamide supramolecular heterosynthons occur at 84% that contain only acid and amide
functional groups. The study of complex formation between acids and amides was of
interest for a long time. The hydrogen bond range and the mean distance obtained from
the CSD for the OH···Narom supramolecular heterosynthon are 2.50-3.10 Å and 2.776 (3)
Å respectively.18 It is found that six of the COU cocrystals (COUNAM, COUINM-I,
COUINM-II, COUTBR, COUINZ) that exhibit this synthon and the hydrogen bond
distances are lower than the mean value (2.776 (3) Å) indicating strong interactions
between the O-H and the Narom moieties. The hydrogen bond distances for the two
cocrystals of COU those are sustained by acid-amide dimer only COUINM-I fall within
the expected range whereas, COUNAM is found to be lower than the mean value for the
acid-amide dimer retrieved from the CSD. The hydrogen bond distances observed for
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various supramolecular synthons sustained by the cocrystals of COU are listed in Table
4.4.
Table 4.4 Various supramolecular synthons observed in COU cocrystals with hydrogen bond
distances as observed in the cocrystals as well as in the CSD.
Supramolecular
Synthon

O-H…Narom

Range (Å) (CSD)

2.50 - 3.10

Mean σ (Å)

2.776 (3)

COUURE

Observed
(Å)
2.705 (2)
2.694 (2)
2.753 (4)
2.732 (2)
2.541 (2)
2.911 (2)
2.493 ()
2.586 (2)
3.040 (2)
2.541 ()
2.911 ()
2.601 (2)

COUINA

2.726 (2)

Cocrystal
COUNAM
COUINM-I
COUINM-II
COUINZ
COUNAM

COOH…Narom

2.4 – 3.10

2.750 (3)

Acid-amide dimer

2.50 - 3.00

2.583 (3)

COUINA
COUINM-I
COUNAM

O-H···C=O
…

-

2.42 – 2.85

2.537 (2)

O-H COO &
COOH…COO-

2.40 - 2.80,
2.42 – 2.86

2.537 (2)

COUBTN

Acid dimer

2.52 – 2.80

2.662 (3)

COURE
COUINA

2.589 (3)
2.650 (2)
2.648 (1)
2.632 (2)

The highest solubility for COU in the dissolution profiles of COU cocrystals
display a wide range of from 0.25 (COUCAF) to 2.08 mg/mL (COUINM-II). The
solubility of pure COU in water is found to be 0.78 mg/mL. Thus, cocrystallization
provided a means to modulate the solubility of COU has been exemplified in the context
of APIs which is well exemplified in the literature where the bioavailability of the API is
limited due to its low solubility or bioavailability. 30,31,32,33 Figure 4.18 (a) and (b)
represents the dissolution profiles of COU and its cocrystals for 24 and 4 hours
respectively. The highest solubility increase of COU (3.4 fold) is exhibited by
COUINM-II (1:2 cocrystal) within the first 5 minutes of the dissolution and eventually
transforms to COUINM-I (1:1 cocrystal) in about 30 minutes.
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(a)

(b)
(b)
Figure 4.18 Dissolution profiles of COU and its cocrystals: (a) 24 h; (b) 4 h.
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The conversion of COUINM cocrystal from Form I to II can also be confirmed from the
PXRD and DSC. The next highest solubilities are exhibited by COUURE and COUBTN
within 30 minutes of the dissolution by 1.8 and 1.5 fold respectively. Surprisingly, CAF
and TBR (both forms) reduced the solubility of COU to almost half of its original
solubility (0.31 and 0.29 mg/mL respectively). The anhydrous form of COUTBR
displayed a little higher solubility for COU when compared to the hydrate form which
gradually converts back to the hydrate form within 30 minutes of the dissolution and rest
of the seven cocrystals increase the solubility of COU. The PXRDs of the left over
powders obtained after the dissolution reveal that out of ten cocrystals eight of the
cocrystals are intact up to 24 h and display uniform solubilities. Two cocrystals
COUBTN and COURE dissociate and fall apart in the solution as evident by the drop in
the solubility of COU by the end of 24 h of dissolution (Figure 3.18 (a)) which
approaches to that of COU.
4.9

Is cocrystal solubility predictable?

There are a handful of studies which have focused on understanding and predicting the
solubility of the cocrystal based on its MP and the solubility of the CCF. In a study
reported by Good and Rodrı´guez-Hornedo to derive a correlation between the solubility
of the cocrystal and the CCF claimed that with increasing solubility of the CCF the
solubility of the CC (carbamazepine, caffeine, and theophylline cocrystals) increases.34
Similar kind of correlation was studied between the MP of the CC and the solubility of
the cocrystal by Newman et al35 and found limited dependence which is attributed to the
multicomponent nature of the cocrystals. Therefore we undertook a similar kind of study
to investigate if there is a correlation between the solubilities of the CC, CCF and the MP
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of the CC. To substantiate the dependence of the solubility of the CC on the CCF
solubility on and the MP of the CC the data obtained from the dissolutions of COU
cocrystals are utilized.
Table 4.5 List of COU cocrystals, MP and Smax
Compound/CC

MP (oC)

Smax (mg/mL)

COU
COUNAM
COUINM-I
COUINM-II
COUCAF (1:2)
COUTHP-III
COUTBR•2H2O
COUTBR
COUINZ
COUURE
COUBTN

225
159
172
166
184
223
228
228
178
124
171

0.811
1.095
1.24
2.082
0.305
1.29
0.289
0.398
1.096
1.569
1.386

It is also important to consider the stability of the CC for the following a correlations
between (a) MP and the solubility of the CC; (b) solubility of the CC and the CCF as the
solubility of a compound depends on various parameters such as temperature, enthalpy of
fusion and intermolecular forces acting between the solute and the solvent and the
particle size of the solute.36,37 Since two of the ten COU cocrystals eventually dissociate
to COU after 24 h dissolution, the concept of Smax used by Bak et al for the correlation
studies is applied for the present study. Smax represents the highest solubility of the CC
exhibited during the 24 h dissolution. Table 4.5 enlists the solubilities and MP of COU
and its cocrystals. Figure 4.19 represents the plot drawn between the MP and Log Smax of
the CC for COU cocrystals. From the plot it is clear that there is low correlation between
the two parameters indicating that it is hard to predict the solubility fromm its MP.
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Figure 4.19 Correlation between the MP and Log S max of the CC.

However, the cocrystals (COUURE, COUBTN, COUINM-I & II and COUNAM)
which have low MP exhibited higher solubilities and vice versa (COUTBR•2H2O,
COUTBR) but these observations are not enough to generalize the correlation between
the MP and Log Smax of the CC. Similarly, there is 50% variability observed in the
relative solubility (log values) of cocrystal and CCF with respect to COU. The 1st
quadrant in the plot (Figure 4.20) the points represent the cocrystal (COUNAM,
COUINM-I & II, COUINZ, COUTHP, COUURE and COUBTN) which have shown
an increase in the solubility of COU significantly. The points in the 3rd quadrant represent
the cocrystals (COUTBR•2H2O, COUTBR) where the CCF has lower solubility than
COU and the cocrystal also decreased the solubility of COU in the cocrystal.

94

Figure 4.20 Correlation between the relative solubility of CCF (Log values) and the cocrystal.

While 4th quadrant represent the cocrystal (COUCAF) which has drastically decreased
the solubility of COU even though the CCF has higher solubility than COU. From our set
of cocrystals and their correlations studies, we have found that it is difficult to predict the
solubility of the cocrystal based on its MP and the CCF.
4.10

Conclusion:

We have successfully demonstrated the utilization of crystal engineering in the design
and synthesis of COU cocrystals with various CCF with varying solubilities. The
experiments resulted in ten novel cocrystals of COU, including a third cocrystal
polymorph with THP. The crystal structure for COUINA and COUBTN were
successfully determined from PXRD patterns. The structures obtained from both the
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techniques were found to be consistent with each other. Most of the cocrystals of COU
exhibit strong either COOH···Narom or O-H···Narom supramolecular heterosynthon. The
results exhibited by COU collectively delineate that this nutraceutical holds a potential to
be used as an efficient CCF because of its capability of forming cocrystals with a variety
of functionalities. Thus it can be used as a potential CCF for APIs.
The dissolution studies of COU and its cocrystals in water display a wide range of
solubilities for COU. The highest solubility was exhibited by COUINM-II followed by
COUURE, COUBTN, COUINM-I and COUINZ. All the cocrystals except COUURE
and COUBTN were found to be stable up to 24 h dissolution. The correlation studies of
COU cocrystals suggest that it is hard to generalize that using a more soluble CCF will
always generate a cocrystal with high solubility for the target molecule or vice versa. One
possibility to account for this variation can be attributed to an insufficient number of
cocrystals with solubility data when compared to the cocrystals reported in the literature.
Therefore, we undertook a study to investigate the correlation studies for all the
cocrystals reported with the solubility data in the literature (unpublished work) and this
report is a part of that study. It is clear from the present data and the existing evidence
from the literature that cocrystallization does indeed have the potential to tailor the
solubility of a compound and could be applied in the field of drug development.
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CHAPTER 5
Multi-Component Crystalline Forms of Hydrochlorothiazide (BCS Class IV drug)
5.1

Introduction

Most of the drugs (nearly 80%) are solids at room temperature and administrated as oral
dosage forms. Solubility and bioavailability are two important parameters of solid state
forms of drug in product development. For every drug the dosage strength is very critical
to attain the required therapeutic concentration and it becomes more critical when the
drug has limited solubility. According to biopharmaceutics classification system (BCS)1
the majority of the drugs which have limited bioavailability due to either low solubility
and permeability fall in to the category of class II and class IV. Solubility of a drug can
be altered either by covalent or noncovalent modifications. The covalent modification2
approaches involve change of the API into a new species whereas in non-covalent
modifications the APIs chemical entity is undiminished. Some of the non-covalent
approaches include the use of excipients (β-cyclodextrins inclusion compounds),3,4 solid
dispersions,5 reduction of particle size (to increase the surface area), 6 amorphous forms,7
micellar/surfactant systems8 and lipids9 to overcome drug limitations such as solubility,
bioavailability and stability.10,11 In the context of solid crystalline forms screening of new
forms such as polymorphs, solvates (pseudo polymorphs) salts and cocrystals provides
the means for improving the solubility and bioavailability of an API. However, salt
formation is confined to ionizable API whereas screening for polymorphs is the matter of
time and money12 spent on the API. Ubiquitously, solvates and hydrates exhibit low
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solubility13,14 when compared to the pure API but of course with some exceptions15
where the solubility is higher. Thus in this situation pharmaceutical cocrystals appear to
be one of the available option. A pharmaceutical cocrystals can be defined “as multiple
component crystals in which at least one component is molecular and a solid at room
temperature (the cocrystal former) and forms a supramolecular synthon with a molecular
or ionic API16”
Pharmaceutical cocrystals represent an alternative approach which allows
tailoring the physico-chemical properties of APIs. These pharmaceutical cocrystals can
be designed rationally utilizing the basic concepts of crystals engineering via the
supramolecular synthon approach. Many scientists within industry and academia have
been fascinated by the results demonstrated by pharmaceutical cocrystals for many
reasons: a) they allow for the modification of non-ionizable APIs, b) they are amenable to
design, c) the presence of various cocrystal formers (CCFs) approved by the FDA as
generally recognized as safe (GRAS) provide an opportunity to select preferred cocrystal
former to achieve tailored property, d) they can be prepared by various methods with
limited or no use of solvents including grinding. The proliferation of this field has been
exemplified by many examples in the literature including several patents
In this context we have targeted hydrochlorothiazide (HCT), a diuretic drug
belonging to the BCS class IV to synthesize pharmaceutical cocrystals and to study how
these cocrystals affect the aqueous solubility in comparison to pure API. HCT suffers
low solubility and low permeability. The low bioavailability of HCT is attributed to its
poor aqueous solubility. Attempts have been made by several groups in order to improve
the solubility of HCT using various techniques. In a study conducted by Padmapriya et
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al, Captopril is used as a water soluble carrier and by varying the concentrations of the
carrier the solubility of HCT was enhanced from 0.246 mg/mL to 0.6125 mg/mL when
compared to the pure form.17 Inclusion compounds of HCT with β-cyclodextrin have also
been synthesized to overcome the solubility limitation. The intrinsic dissolution of the
inclusion compounds in simulated gastric fluid exhibited an increase in the solubility. In
this contribution we report pharmaceutical cocrystals of HCT designed through crystal
engineering studies with the aid of the Cambridge Structural Database (CSD).
A thorough CSD search revealed the presence of two polymorphic forms of HCT
(Ref code: HCSBTZ, HCSBTZ01) and nine solvated forms. Nevertheless, four
polymorphic forms of HCT were reported in a study conducted by Kim et al 18 on the
polymorphic nature of HCT and they were characterized by powder X-ray diffraction
(PXRD) and differential scanning calorimetry (DSC).

(i)

(ii)

Figure 5.1 Two polymorphic forms of HCT: HCSBTZ (left) and HCSBTZ01 (right)

Figure 5.1 represents the two polymorphs of HCT reported in the CSD. In Form-I four
HCT molecules form a tetramer whereas, in Form-II the 2o sulfonamide engages in the
formation of a dimer. No cocrystals of HCT are reported in the CSD however, three
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cocrystals of HCT with nicotinic acid, 18-crown-6 and piperazine have been in a patented
by Almarson and Zaworotko et al. HCT has multiple acceptors and donors which makes
it a potential candidate for crystal engineering studies. The CSD contains a handful of
examples on the cocrystallization of sulfonamide drugs of which most of them are amino
substituted benzenesulfonamide APIs. Caira et al has done an extensive study on the
cocrystallization of sulfa drugs, which included sulfadimidine as a model cocrystal
former with several carboxylic acids.19 Piroxicam, (BCS Class II sulfonamide drug) was
studied by Childs et al20 for cocrystallization using carboxylic acids as CCFs. Celecoxib
(4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl]

benzene-sulfonamide)

is

another low soluble API which was targeted for cocrystallization by Hickey et al.21 They
reported one cocrystal of celecoxib with nicotinamide (VIGDAR) which exhibit
enhanced solubility when compared to the pure drug.
5.2

Selection of CCFs for HCT based on supramolecular synthon approach via
CSD analysis

For simplicity the CSD search for HCT was carried out in two fragments. The first
fragment contains the sulfonamide (both 1o and 2o) moiety and the second contains the 2o
amine (Figure 5.2). Chloride being a weak acceptor was not included in the search.
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Figure 5.2 Moieties used during CSD searches for HCT.

Searches were conducted individually for each fragment with different functional groups
including carboxylic acids, phenols, basic nitrogen, amides and carboxylates. Table 5.1
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represents various possible interactions of fragments I and II with different functionalities
and Table 5.2 enlists the CSD statistics obtained from these searches.
The CSD statistics reveal that certain functionalities such as amides (71%), Narom
(65%) and carboxylates (50%) hydrogen bond to various moieties of HCT at higher
percentages while the other supramolecular synthons occur at lower percentages.
Therefore, appropriate CCFs such as amides, basic nitrogen compounds and carboxylates
would be best suitable for cocrystallization experiments for HCT. Functional groups such
as amides, phenols and carboxylates are well studied in the context of supramolecular
synthons. Zaworotko et al. have studied the underexplored carboxylates moieties with 2aminopyridinium22 and weakly acidic hydroxyl moieties23.
Table 5.1 Possible supramolecular heterosynthons for HCT with other functionalities
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It was found that 2-aminopyridinium-carboxylate supramolecular heterosynthon
occurs at 97% and weakly acid hydroxyl-carboxylate supramolecular heterosynthon
occurs at 56%. This shows that carboxylate moieties are still to be explored with other
functionalities to a greater extent. Thus, using CCFs with carboxylates moieties for HCT
offers a means to explore them with sulfonamide functionalities. The cocrystal of HCT
with isonicotinamide (INM) is published elsewhere but is included in here for dissolution
studies.
Table 5.2 CSD statistics of possible supramolecular synthons in HCT with different functionalities.

Sulfonamide + acid

132

Sulfonamide + amide

17

Sulfonamide + phenols

60

2o amine + acid

610

2o amine + amide
2o amine + Narom

100
1070

Hits that form supramolecular
heterosynthon with % of occurrence
III=39 (30%),
VI =4 (3%),
IX=10 (8%)
II=12 (71%),
V=12 (71%)
I=9 (15%),
IV=16 (27%)
XIII=9 (1%),
XIV=137 (22%)
XII=26 (26%)
X=298 (28%)

2o amine + carboxylate

70

XI=17 (24%)

Sulfonamide + Narom
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VII=68 (65%)

Sulfonamide + carboxylate

2

VIII=1 (50%)

Total hits

5.3

Materials and Methods

All reagents were obtained from commercial suppliers and used without further
purification. All solvents were distilled prior to their use. The molecular structures of
HCT and the CCFs (with their three letter code) are represented in Figure 5.3.
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Figure 5.3 Molecular structures of HCT and the CCFs.

5.3.1

Preparation of single crystals: Single crystals for the cocrystals are obtained by

dissolving the starting materials in appropriate solvent(s) followed by slow evaporation.
All reagents were obtained from commercial suppliers and used as such without further
purification. Specific details are as follows:
Hydrochlorothiazide • Nicotinamide, HCTNAM: Hydrochlorothiazide, 15 mg (0.1000
mmol) and nicotinamide, 61.0 mg (0.5000 mmol) were added to 4 mL of ethyl acetate
and heated on a hotplate. The resulting solution was filtered using a filter paper and
placed in the hood for slow evaporation. Colorless crystals of HCTNAM were harvested
after two days (melting point =177.9°C).
Hydrochlorothiazide • Nicotinic acid, HCTNAC: Hydrochlorothiazide, 15mg (0.050
mmol) and nicotinic acid, 12.1 mg (0.100 mmol) were added to 4 mL of 1:1
methanol/water and heated on a hotplate. The resulting solution was placed in the hood
for slow evaporation. Colorless crystals of HCTNAC were harvested after four days
(melting point =267.9oC).
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Hydrochlorothiazide • Betaine, HCTBTN: Hydrochlorothiazide, 20 mg (0.067 mmol)
was added to 3 mL saturated solution of betaine in ethanol. The resulting solution was
heated on a hotplate and was left at room temperature for slow evaporation. Colorless
needles of HCTBTN were harvested after three days (melting point =220°C).
Hydrochlorothiazide • Dimethylglycine, HCTDMG: Hydrochlorothiazide, 300 mg
(1.01 mmol) and dimethyl glycine, 500 mg (4.85mmol) were added to 7 mL of ethanol
and heated on a hotplate until a clear solution was obtained. The resulting solution was
placed in the hood for slow evaporation. Colorless crystals of HCTDMG were harvested
after a week (melting point =206.3°C).
The synthesis and the structure description of the cocrystal of HCT with isonicotinamide
(HCTINM•H2O) has been reported elsewhere.
5.3.2

Preparation of cocrystals via slurry: Stoichiometric amounts of starting

materials were slurried in ethanol overnight (1 mL of EtOH, per 500 mg of starting
material). The undissolved solid is isolated by filtration and characterized using PXRD,
DSC and FT-IR.
5.3.3

Differential scanning calorimetry (DSC): Thermal analysis was performed on a

TA Instruments DSC 2920 Differential Scanning Calorimeter. Aluminum pans were used
for all samples and the instrument was calibrated using an indium standard. For
reference, an empty pan sealed in the same way as the sample was used. Using inert
nitrogen conditions, the samples were heated in the DSC cell from 30°C to the required
temperature (melting point of the cocrystal) at a rate of 10°C/min.
5.3.4

Thermogravimetric analysis (TGA): A Perkin Elmer STA 6000 Simultaneous

Thermal Analyzer was used to conduct thermogravimetric analysis. Open alumina
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crucible is used to heat the sample from 30°C to the required temperature at 10 °C/min
scanning rate under nitrogen stream.
5.3.5

Infrared spectroscopy (FT-IR): To characterize the cocrystals by infrared

spectroscopy a Nicolet Avatar 320 FT-IR instrument was used. Sample amounts of 1-2
mg were used and spectra were measured over the range of 4000 – 400cm-1 and analyzed
using EZ Omnic software.
5.3.6

Powder X-ray diffraction (PXRD): A Bruker AXS D8 powder diffractometer

was used for all PXRD measurements with experimental parameters as follows: Cu Kα
radiation (λ = 1.54056 Ǻ); 40 kV and 30 mA. Scanning interval: 3–40° 2θ; time per step:
0.5 sec. The experimental PXRD patterns and calculated PXRD patterns from single
crystal structures were compared to confirm the composition of bulk materials.
5.3.7

Single-crystal X-ray data collection and structure determinations: Crystals

suitable for X-ray crystallography were selected using an optical microscope. Data for the
cocrystals were collected on Bruker-AXS SMART APEXII CCD diffractometer with
monochromatized Cu Kα radiation (λ = 1.54178 Å) connected to a KRYO-FLEX low
temperature device. Indexing was performed using SMART V5.625

24(a)

or using APEX

2008 V1-0.11(b) Frames were integrated with Saint Plus 7.5111(c) software package.
Absorption correction was performed by multi-scan method implemented in
SADABS.11(d) The structures were solved using SHELXS-97 and refined using SHELXL97 contained in SHELXTL V6.1011(e) and WinGX V1.70.0111(f, g, h) programs packages.
All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were placed in
geometrically calculated positions or found in the Fourier difference map and included in
the refinement process using riding model or without constraints. Table 5.3 contains the
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crystallographic data and structure refinement parameters for the cocrystals isolated in
the present study.
Table 5.3 Crystallographic data and structure refinement parameters for the cocrystals.

Formula
MW
Crystal system

HCTNAC

HCTBTN

HCTDMG

C13H14ClN5O5S2
419.86
Orthorhombic

C13H13ClN4O6S2
420.84
Orthorhombic

C12H19ClN4O6S2
414.88
Monoclinic

C15H26ClN5O8S2
503.98
Triclinic

Space group

P212121

P212121

P21/c

P-1

a (Å)

7.6392 (2)

7.3412 (3)

9.8569 (2)

10.3649 (7)

b (Å)

13.2595 (4)

12.9934 (6)

21.6404 (5)

10.7143 (8)

c (Å)

16.1215 (5)

16.1869 (7)

8.0471 (2)

11.5908 (8)

 (deg)

90

90

90

78.513 (4)

 (deg)

90

90

91.507 (1)

68.481 (4)

 (deg)

90

90

90

67.970 (4)

3

5.3.8

HCTNAM

V /Å

1632.98 (8)

1544.02 (12)

1715.91 (7)

1107.21 (14)

Dc/g cm-3

1.708

1.810

1.606

1.512

Z

4

4

4

2

2 range

4.32 to 67.92

4.36 to 67.14

4.49 to 67.26

4.11 to 65.64

Nref./Npara.

2871 / 245

2629 / 229

2997 / 278

3638 / 301

T /K

100 (2)

100 (2)

100 (2)

100 (2)

R1 [I>2sigma(I)]

0.0283

0.0514

0.0366

0.0491

wR2

0.0682

0.1160

0.0939

0.1300

GOF

1.051

0.972

1.047

1.007

Abs coef.

4.836

5.148

4.613

3.765

Cocrystal Solubility Evaluation: Solubility studies were performed on HCT

cocrystals including HCTINM•H2O using HPLC in aqueous media. A uniform particle
size (between 53 and 75 μm) for the bulk powder was obtained for all the cocrystals and
pure HCT by sieving. The dissolution studies are conducted by taking approximately 4
grams of the cocrystal in 40 mL of water and were stirred with magnetic stir bar at ca.
125 rmp for 24 hours. An aliquot is drawn from the slurry after 24 hours in order to
obtain the thermodynamic solubility of HCT in the cocrystal and filtered using a 0.45 μm
nylon filter. The filtrate are diluted appropriately and analyzed via HPLC to measure the
concentration of HCT. The remaining solid is analyzed by PXRD and DSC to confirm
the identity. The solubility measurements were done triplicates.
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5.4

Description of Crystal Structures

5.4.1

HCTNAM: The cocrystal HCTNAM is a 1:1 cocrystal of HCT and NAM as

revealed by the crystal structure. The carbonyl moiety of the amide group in NAM
molecule hydrogen bond with the sulfonamide moiety of HCT molecule (O···N-H: 3.041
(3) Å) as represented in Figure 5.4. The NAM molecules also involves in hydrogen
bonding in a head-to-tail fashion with each other, consequently parallel tapes of NAM
molecules (N-H···Narom: 2.873 (3) Å) are formed. Ultimately, ribbons of HCT-NAM are
generated that interacts with other ribbons above and below the plane through N-H···O
(2.901 (3) Å) hydrogen bonds as shown in Figure 5.5

Figure 5.4 Representation of intermolecular hydrogen bonds in HCTNAM

The HCT molecules in one tape interacts with other HCT molecules in the adjacent tapes
via N-H···S=O interactions (2.901 (3) Å). The CSD search for sulfonamide cocrystals
revealed the presence of four cocrystals with NAM, tartaric acid, antipyrine (phenazone)
and sulfanilamide as cocrystal formers. In the cocrystal of NAM (VIGDAR)25 with
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celecoxib, NAM molecules maintain the amide dimer, whereas the sulfonyl moieties
hydrogen bond to the anti-hydrogens of the amide groups of NAM molecules. To the
contrary, in HCTNAM, the amide dimers of NAM molecules are broken and O···N-H
prevails as the dominant supramolecular heterosynthon.

Figure 5.5: Overall H-bonding in HCTNAM.

5.4.2

HCTNAC: In the 1:1 cocrystal of HCTNAC, the NAC molecules exist as

zwitterions supported by the C-O bond distances, 1.252 and 1.261 Å, and the C-N-C
bond angle of 123o. Pure NAC exhibits C-O bond distances of 1.25 Å and 1.289 Å and a
C-N-C bond angle of 117.9o.

Figure 5.6 Intermolecular hydrogen bonding in the tape formed in HCTNAC.

112

The NAC molecules exhibit the formation of head-to-tail chains (O···Narom: 2.639 (2) Å)
as in pure NAC crystal structure. The HCT molecules also form linear tapes adjacent to
the NAC chains which are H-bonded to each other via charge assisted O···N-H bonds
(2.943 (2) Å) as illustrated in Figure 5.6.

Figure 5.7: Lateral interactions of HCT molecules on HCTNAC (NAC molecules are removed for
clarity).

Each tape interacts on either sides through H-bonding between HCT molecules via NH···S=O interactions (2.921 (2) Å) as presented in Figure 5.6 and Figure 5.7 represents
the overall hydrogen bonding in HCTNAC. The H-bonding in HCTNAC resembles to
that of in HCTNAM. The overall supramolecular hydrogen bonding results in the
formation of corrugated tapes that are stabilized by π- π stacking as represented in Figure
5.8.

Figure 5.8: Interconnections of the adjacent tapes via H-bonds in HCTNAC.
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5.4.3

HCTBTN: The successful cocrystallization resulted in the formation of

HCTBTN. The crystal structure of HCTBTN reveals that it is a 1:1 cocrystal of HCT
and BTN where, the BTN molecules are disordered. The carboxylate moiety of BTN is
involved in multiple hydrogen bonds. It interacts with the 1o sulfonamide and the amine
functionality of adjacent HCT molecules. The hydrogen bond distances of the
carboxylate with the 1o sulfonamide were found to be 2.867 (3) Å and 2.974 (2) Å
whereas the bond distances with amine functionality was 2.892 (2) Å (Figure 5.9).

Figure 5.9 Formation of a linear chain between HCT and BTN molecules in the cocrystal.

The linear chains formed in HCTBTN interact with each other via H-bonds formed
between the 1o sulfonamide moiety of HCT with the 1o sulfonamide moiety of another
HCT molecule via N-H···S=O (2.862 (2) Å) interaction. The carboxylate also interacts
with the 2o sulfonamide moiety of HCT via O···N-H hydrogen bond (2.827 (2) Å). The
overall hydrogen bonding results in the formation of parallel corrugated tapes which
stack one above the other and stabilize by π- π stacking as shown in Figure 5.10.
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Figure 5.10 Intermolecular hydrogen bonding in the monohydrate of 1:1 HCTBTN cocrystal.

5.4.4

HCTDMG: The cocrystallization between HCT and DMG resulted in 1:2

cocrystal that crystallizes in P-1 space group with two independent DMG molecules.
Unusually, no two HCT molecules interact with each other directly.

Figure 5.11 Hydrogen bonding between HCT and DMG in the cocrystal.

The carboxylate moiety of the DMG molecules connects two neighboring HCT
molecules through N-H···COO- (one N-H of the 1o amine, 2.917 (3) Å and the other of
the 2o sulfonamide group, 2.860 (2) Å) as illustrated in Figure 5.11. Two such tapes as
illustrated Figure 5.12 are connected to each other via bifurcated H-bonds formed by the
carboxylate moiety in the first layer with the 1o amine, 2.894 (3) Å and the other of the 2o
sulfonamide group 2.827 (2) Å present in the second layer between them. Similarly, the
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carboxylate of the DMG molecule in the second layer forms bifurcated H-bonds with
HCT present in the first layer. However, the DMG molecules (blue) which connects the
HCT molecules in one tape is connected to another DMG molecule present in the
adjacent tape via a dimer formed by second independent (magenta) DMG molecules by
N-H···O- ( 2.761 (2) Å) as shown in Figure 5.12.

Figure 5.12 Overall H-bonding in HCTDMG. HCT molecules are colored in green, while two
independent DMG molecules are colored in magenta and blue.

5.5

Discussion

Cocrystallization attempts of HCT resulted in the isolation of five cocrystals with CCFs
that contain amides and carboxylate functionalities. This offer a means to explore and
study certain functionalities like sulfonamides and carboxylates which are under explored
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from supramolecular perspective. The only one cocrystal which was isolated as a hydrate
was HCTINM•H2O and the stability of the cocrystal upon the removal of water from the
crystal has been thoroughly studied in one our recent publication on hydrate cocrystals.
The amide dimer of INM is intact in HCTINM•H2O cocrystal whereas that has been
overcome by N-H···O supramolecular heterosynthon in HCTNAM. In HCTNAC the
carboxylate only interacts with the N-H of the 1o sulfonamide moiety whereas in
HCTBTN and HCTDMG the carboxylate interacts with all the functional moieties
present in HCT molecule namely, 1o and 2o sulfonamide moieties and 2o amine.
Carboxylic acids were not successful CCFs for cocrystallization with HCT as they were
with many other sulfa drugs reported by Caira et al.18 This is understandable because
most of the sulfa drug cocrystals contain Narom moiety in their structures that have been
reported in the CSD. As carboxylic functionalities form a robust supramolecular
heterosynthon with Narom moiety and this has been exemplified exemplified by one of
our hierarchy study of supramolecular heterosynthons. According to which the carboxylic
acid groups are more suitable for Narom moieties for cocrystallization as the chances of
interactions between these functionalities is 97 % (in the absence of other competing
functionalities which has been already established by Shattock et al.26 Some examples of
sulfa drugs such as celecoxib, sulfathiazole and sulfadimidine are presented in Figure
5.13 which contains sulfonamide groups fused to six or five membered ring systems with
Narom.

While for HCT, the formation of a cocrystal depends on the reliability of

sulfonamide (1o and 2o), 2o amine and chloride moieties to form cocrystal and makes it
quite different from the rest. But, we cannot rule out the possibility of carboxylic acid as
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CCFs as the right stoichiometry, solvent and suitable method may not have been explored
for HCT yet.

(a)

(b)

(c)

Figure 5.13 Some examples of sulfa drugs containing Narom moieties in them. Celecoxib (a);
sulfadimidine (b); sulfathiazole (c).

The effect of cocrystallization on the solubility of HCT was also investigated.
Thermodynamic solubility of the cocrystals was determined by dissolving excess amount
of cocrystal in water for 24 h (Table 5.4). When compared to the solubility of HCT four
cocrystals, namely HCTNAM, HCTINM•H2O, HCTBTN and HCTDMG showed an
increase in the solubility of HCT. The highest solubility was exhibited by HCTDMG
(1.87 mg/mL, 7-fold increase) followed by HCTBTN (1.68 mg/mL). HCTNAM and
HCTINM•H2O exhibited almost an increase of 5-fold solubility.
Table 5.4 Solubility and MP of HCT and its cocrystals.
Compound

Melting Point
(oC)

Solubility in water
mg/mL (24 h)

HCT

275

0.25

HCTBTN

220

1.68

HCTDMG

206

1.87

HCTINM•H2O

127

1.26

HCTNAC

268

0.1

HCTNAM

178

1.33
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Surprisingly, HCTNAC displayed a lower solubility than HCT and also the highest MP
but, the vice versa is not true. Therefore it is difficult to say that in case of HCT cocrystal
the MP is the key factor to predict the solubility. Parameters such as crystal packing and
MP are often times used as parameter to predict the aqueous solubility and
viscosity.26,27,28 The literature contains examples of number of studies to establish a
relationship between solubility and the MP of a compound including cocrystals.

29,30,31

From various studies it is found that it is difficult to draw a correlation between such
parameters for organic compounds as there are various other factors that control
solubility.32 The complex nature of cocrystals further complicates the prediction as the
prominent interactions in cocrystals are the intermolecular hydrogen bonds which also do
affect the MP which in turn impacts the solubility. Similarly attempts were made to
correlate the solubility of the cocrystal with the solubility of the cocrystal former.33 It was
found that there is direct correlation between the solubility of the cocrystal components
and the cocrystal solubility. However, limited or no such kind of correlation was
observed in HCT cocrystals. To determine the chemical identity of the cocrystal, the
powder obtained after 24 h was analyzed. The PXRD of the powders retrieved for
HCTDMG and HCTBTN after 24 h reveal the dissociation of the cocrystal in to HCT
whereas, the cocrystals HCTNAM, HCTINM•H2O and HCTNAC maintains the
cocrystal integrity. Thus, the solubility of HCT obtained after 24 h for HCTBTN and
HCTDMG does not reflect the solubility of the cocrystal. Future work would focus up on
the permeability testing of HCT cocrystals.
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5.6

Conclusion

HCT which is quite different from other sulfa drugs in terms of acceptors and donors has
been explored for cocrystallization. The work presented herein demonstrates how the
basic concepts of crystal engineering could be utilized in the form of cocrystallization to
modulate the solubility of low solubility APIs. Four new crystalline forms of HCT, a
class IV drug have been isolated as cocrystals. The highest solubility was exhibited by
HCTDMG whereas the lowest by HCTNAC. All the cocrystals of HCT with zwitterions
exhibit synthon VIII where the carboxylate interacts with sulfonamide functionality. The
results delineate that zwitterions, especially the amino acids, stand out as more
appropriate CCFs for sulfonamide drugs like HCT (not containing Narom moiety). Amino
acids being safe and less expensive with high water solubility make them suitable CCFs.
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CHAPTER 6
Ionic Cocrystals of Li salts with Homochiral and Achiral Amino Acid Zwitterions

6.1

Introduction

Cocrystals, “long known compounds”1 have immensely attracted the scientific
community and are under continuous study for many applications involving, but not
limited to, pharmaceuticals2, nutraceuticals3, hydrogels4, purification/chiral separations5,
organic conductors6, dyes7 , luminescence8, sorbents9, organocatalysis10, explosives11 and
non-linear optical materials12, photographic materials13. Moreover, cocrystals also
provide a means to discover new supramolecular synthons which is the ultimate key to
molecular assembly. Many supramolecular synthons have been discovered and new
hierarchies are also being developed which can serve as a design tool for cocrystal
synthesis. Until now most of the reported cocrystals consists of two organic components
but, more recently the focus has been moved to organic-inorganic hybrid cocrystals.
Braga et al14 and Zaworotko et al15 have reported cocrystals which consist of an organic
molecule and an inorganic salt (especially alkali and alkaline metal salts). The coalition
between organic and inorganic molecules results in a hybrid class of cocrystals which
were not explored systematically until now since they were reported many decades
before.
6.2

Ionic cocrystals

Nevertheless, cocrystals are considered to be one of the important outcomes of crystal
engineering within which many research groups have focused their interest.16,17 A
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cocrystal can be defined as a stoichiometric multiple component crystal formed between
two compounds that, when pure, are solid under ambient conditions: at least one
component is molecular and forms a supramolecular synthon with the remaining
components via non-covalent interactions. Primarily, non-covalent interactions include
hydrogen bonding, coordination bonds, hydrophobic forces, π-π interactions, electrostatic
effects and van der Waals forces. The bond strength ranges from several hundred kJ/mol
(coordination bonds) to only a few kJ/mol (van der Waals forces).18 Therefore, any two
components which adhere to the entire criterion mentioned above in the cocrystal
definition should fall under cocrystal category. Thus, in an ionic cocrystal one of the
component is molecular (cocrystal former 1) and the other component is an inorganic salt
(cocrystal former 2) which interact with each other via non-covalent interactions
including coordinate bonds. Consequently, ionic cocrystals are justified class of
cocrystals and should be recognized as one without any discrepancy.

Though a

serendipitous invention, ionic cocrystal gives a new perspective to look at cocrystals.
Notwithstanding that ionic cocrystals have been isolated in the late 1940s19, this field
remains relatively underexplored. Therefore, systematic study for the hybridization of
organic-inorganic components in the context of ionic cocrystal is worth studying.
6.3

Crystal engineering of Lithium salts

6.3.1

Design perspective: In most of the Li complexes, lithium ions are observed to

interact with an oxygen atom to a greater extent than to any other atoms. Complexes
wherein lithium interacts with nitrogen or sulfur atoms are comparatively less in number.
The order of the stability of Li complexes with ligand donor atoms oxygen, nitrogen and
sulfur is O > N > S.20

Because of its small size, Li exhibits a large variety of
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coordination numbers and geometry. The coordination numbers vary from 2 to 8 in its
complexes and the most predominant coordination numbers are 4, 5 and 6.25 From an
electrostatic point of view, the tetrahedral (Td) configuration is the most stable.15
Similarly, naturally occurring zeolites such as analcime, chabazite, clinoptilolite,
heulandite, natrolite, phillipsite etc are sustained via tetrahedral nodes resulting in 3-D
microporous networks. Inspired by nature many synthetic zeolites have been synthesized
with a wide range of topologies by utilizing angular oxide linkers with metals in the
stoichiometry of 2:1 ratio.21
6.3.2

Drug perspective: From early 19th century Li in the form of Li+ ion had been

used as a drug for treating gout owing to its ability to dissolve uric acid crystals isolated
from the kidneys. From the 1870s onwards it was in use for mania treatment and also
used a antipsychotic drug with no/minimal suicidal tendencies.22,23 By the early 1920’s Li
(Lithium citrate) was in use as an ingredient in soda beverages as a mood stabilizer
marketed under names such as "Bib-Label Lithiated Lemon-Lime Soda and 7 Up. It is
believed that once ingested Li interacts with a number of neurotransmitters and receptors
through central nervous system which in turn decreases the release of norepinephrine and
increases the synthesis of serotonin. But the use of Li was soon ceased due severe side
effects. The narrow therapeutic index of Li salts limits its use as a therapeutic drug. 24 For
bipolar disorder the therapeutic concentration is 0.6-1.2 mEq/L and the Li toxicity could
take place once the concentration is > 1.5 mEq/L. The Tmax for most of the Li salts the
blood serum is about 2 h whereas for the brain is around 24 h. To make the things worse
Li experiences difficulty in passing the blood brain barrier (BBB) and this leads to the
accumulation of Li in various vital organs of the body. Thus, patients have to be
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continuously monitored for Li overdose and toxicity which restricts the treatment to carry
out for patients in smaller and continuous doses. Cocrystallization of Li salts with
acceptable cocrystal formers such as amino acids could serve as an alternative to the issue
mentioned above for the following reasons: (a) amino acids are transported to the brain
via many active transporters and are therefore good choice for cocrystallization with Li
salts; (b) cocrystals can manipulate the physico-chemical properties and could alter the
bioavailability of Li salts via cocrystallization; (c) since cocrystals are novel and hence
patentable; (d) amino acids have carboxylate moiety that can strongly interact with Li
cation via coordination bond.
In this attempt, we undertook the study of synthesizing ionic cocrystals of lithium
salts and amino acid zwitterions. In one of our recent publications14, we have highlighted
the use of homochiral and achiral amino acid zwitterions to develop a strategy for
lithium-based ionic cocrystals with amino acid zwitterions. This strategy was
materialized in producing 1:2 cocrystals of Li salts namely, lithium chloride (LIC),
lithium bromide (LIB) and lithium nitrate (LIN) with amino acid zwitterions cocrystals
with different topologies including zeolites, square grids and diamondoids. Thus, it is
clear that stoichiometry is the key factor for determining topology in Li-amino acid
zwitterion based cocrystals. Selection of amino acid zwitterions for cocrystal design has
also been exemplified in some of our earlier results.25 The CSD contains eight ionic
cocrystals of LIC, LIB and LIN with amino acids (LIB cocrystals = ALGLYL26,
GLYGLB, GLYLIB; LIC cocrystals = HEFWUK27, HEFXEV, YOXBET28; LIN
cocrystals = ALUNEA29, ROZTUW30). The ionic cocrystals of LIC and LIB including
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some of the LIN with amino acids (1:1 and 1:2 cocrystals) have been reported
elsewhere.14,31
6.4

Experimental Section

The CCFs (with their three letter code) listed in Figure 6.1 are used for cocrystallization
experiments for Li salts. All reagents were obtained from commercial suppliers and used
without further purification.
H2N

O
O
H2N

OH

Beta Alanine (BAL)

H2N
HO

O
OH

L-Serine (SER)

N

H2N

OH
Dimethylglycine (DMG)

H2N

O

O
OH

OH

Amino butyric acid (ABA)

L-Leucine (LEU)

COOH

O

COOH

N
OH
N
H
Histidine (HIS)

N

N
Isonicotinic acid (NAC)

Nicotinic acid (NAC)

Figure 6.1 List of cocrystal formers with three letter code.

6.4.1

Preparation of single crystals: Single crystals for the cocrystals are obtained by

dissolving the starting materials in appropriate ratio in distilled water followed by
evaporation. Specific details are as follows:
LICLEU: Lithium chloride, anhydrous, 253.8 mg (6.0 mmol) and leucine, 40 mg (0.3
mmol) were dissolved in 5 mL of deionized water and left on the hot plate evaporated on
a hot plate until crystals emerged from the hot solution.
LINABA: Lithium nitrate, 413.4 mg (6.0 mmol) and 4-aminobutyric acid, 618.6 mg (6.0
mmol) were dissolved in 4.0 mL of hot deionized water and evaporated on a hot plate
until crystals emerged from the hot solution. Colorless rod crystals were collected from
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the hot solution.
LINBAL: Lithium nitrate, 413.4 mg (6.0 mmol) and β-alanine, 534.5 mg (6.0 mmol)
were dissolved in 2.0 mL of hot deionized water. The solution was maintained on a hot
plate until crystals emerged from the hot solution. Colorless crystals were collected from
the hot solution.
LINHIS: Lithium nitrate, 413.4 mg (6.0 mmol) and L-histidine, 50 mg (0.32 mmol) were
dissolved in 5.0 mL of hot deionised water. It was maintained on a hot plate until crystals
emerged from the hot solution. Colorless plates were collected from the hot solution.
LININA: Lithium nitrate, 413.4 mg (6.0 mmol) and isonicotinic acid, 40 mg (0.325
mmol) were dissolved in 3 mL of deionised water. It was maintained on the hot plate
until crystals emerged from the hot solution. Colorless crystals were collected from the
hot solution and used for further analysis.
LINNAC: Lithium nitrate, 413.4 mg (6.0 mmol) and nicotinic acid, 80 mg (0.65 mmol)
were dissolved in 3 mL of deionised water. It was maintained on the hot plate until
crystals emerged from the hot solution. Colorless plates were collected from the hot
solution and used for further analysis.
LINDMG2: Lithium nitrate, 413.4 mg (6.0 mmol) and N, N-dimethylglycine 1236 mg
(12.0 mmol) were dissolved in 3.0 mL of hot deionised water. It was maintained on the
hot plate until crystals emerged from the hot solution. Colorless plates were collected
from the hot solution.
LINSER2: Lithium nitrate (99%, anhydrous, used as received from Acros Organics, 414
mg, 6.0 mmol) and L-serine (used as received from Acros Organics, 635.4 mg, 6.0 mmol)
were dissolved in 3.0 mL of hot deionised water. It was maintained on the hot plate until
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crystals emerged from the hot solution. Colorless rods were collected from the hot
solution.
6.4.2

Differential scanning calorimetry (DSC): Thermal analysis was performed on a

TA Instruments DSC 2920 Differential Scanning Calorimeter. Aluminum pans were used
for all samples and the instrument was calibrated using an indium standard. For
reference, an empty pan sealed in the same way as the sample was used. Using inert
nitrogen conditions, the samples were heated in the DSC cell from 30°C to the melting
point of the cocrystal at a rate of 10°C/min
6.4.3

Thermogravimetric analysis (TGA): A Perkin Elmer STA 6000 Simultaneous

Thermal Analyzer was used to conduct thermogravimetric analysis. Open alumina
crucibles were used to heat the samples from 30°C to the required temperature at 10
°C/min scanning rate under nitrogen stream.
6.4.4

Infrared spectroscopy (FT-IR): Characterization of the cocrystals by infrared

spectroscopy was accomplished with a Nicolet Avatar 320 FT-IR instrument. Sample
amounts of 1-2 mg were used and spectra were measured over the range of 4000 –
400cm-1 and analyzed using EZ Omnic software.
6.4.5

Powder X-ray diffraction (PXRD): A Bruker AXS D8 X-ray powder

diffractometer was used for all PXRD measurements with experimental parameters as
follows: Cu Kα radiation (λ = 1.54056 Ǻ); 40 kV and 30 mA; Detector type: Scintillation
type; Scanning interval: 3-40° 2θ; time per step: 0.2 sec. The experimental and calculated
PXRD patterns from single crystal structures were compared to confirm the composition
of bulk materials.
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6.4.6

Single-Crystal X-ray Data Collection and Structure Determination: Crystals

suitable for X-ray crystallography were selected using an optical microscope. Data for the
cocrystals were collected on Bruker-AXS SMART APEXII CCD diffractometer with
monochromatized Cu Kα radiation (λ = 1.54178 Å) connected to a KRYO-FLEX low
temperature device. Indexing was performed using SMART V5.6 or using APEX 2008
V1-0. Frames were integrated with Saint Plus 7.51 software package. Absorption
correction was performed by multi-scan method implemented in SADABS. The
structures were solved using SHELXS-97 and refined using SHELXL-97 contained in
SHELXTL V6.10 and WinGX V1.70.01 programs packages. All non-hydrogen atoms
were refined anisotropically. Hydrogen atoms were placed in geometrically calculated
positions or found in the Fourier difference map and included in the refinement process
using riding model or without constraints. The crystallographic data for the cocrystals
reported herein are presented in Table 6.3.
6.5

Crystal Structure Descriptions

6.5.1

LICLEU: The X-ray structure reveals a 1:1 LIC and LEU cocrystal hydrate. Each

lithium cation is coordinated by three bridging carboxylates (Li-O: 1.947 Å, 1.966 Å and
1.981 Å). One water molecule coordinates to Li atom to complete its tetrahedral
coordination (Li-O: 1.921 Å). The chloride anions reside in the crystal unit and
participate in the H-bonding with the nitrogen atom in the RNH3+ cation of the amino
acid (Cl···N-H: 3.169 (2) Å and 3.180 (2) Å). It also H-bonds to two water molecules of
the adjacent tape (Cl···O-H: 3.183 (3) Å and 3.208 (2) Å). Figure 6.2 illustrates the
overall network in LICLEU.
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Figure 6.2 1-D tape in LICLEU monohydrate.

6.5.2

LINABA: The 1:1 cocrystal of LIN and ABA cocrystallize in P21/n space group.

Each Li atom is coordinated to two carboxylate anions of ABA with bond distances Li-O:
1.897 and 1.946 Å.

Figure 6.3 Illustration of square grids in LINABA.

The nitrate anions acts as bridging ligands and bind to Li atom completing its tetrahedral
geometry. The coordinate bond distances observed between the Li atom and the nitrate
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anions are 1.975 and 2.047 Å. The overall structure in LINABA results in a square grid
network as shown in the Figure 6.3.
6.5.3

LINBAL: The cocrystallization of LiNO3 and beta-alanine results in the

formation of 2:3 cocrystal. The LINBAL cocrystal also results in the formation of 1-D
tape as in LICPRO, LICBAL-I.

Figure 6.4 Formation of linear 1-D tape in LINBAL.

The only difference being the bridging of water molecule to the metal to complete the
tetrahedral coordination environment whereas, in LINBAL the fourth coordination of Li
metal is satisfied by the nitrate anion. Thus, the overall coordination of BAL molecules
and the nitrates anions to the Li atom results in the formation of a linear tape as shown in
Figure 6.4.
6.5.4

LINHIS: Cocrystallization between LIN and HIS results in the formation of a 1:1

cocrystal. Each of the Li atom is coordinated to three neighboring carboxylates of HIS
molecules. The fourth coordination of Li is fulfilled by water molecule. Li-O distances
(Li to carboxylate oxygen) observed in LINHIS are 1.875 Å, 1.955 Å, 1.962 Å. The
nitrate anion resides in the crystal packing without coordinating to any atom; nevertheless
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it is involved in H-bonding with the ammonium group (RNH3+) and NH moiety of the
imidazole ring of HIS molecule. The Narom of the imidazole ring also H-bonds to the
ammonium group (RNH3+). The overall coordination between LIN and HIS results in the
formation of linear 1-D tape as presented in Figure 6.5.

Figure 6.5 Illustration of 1-periodic network in LINHIS (hydrogen atoms have been removed for
clarity).

6.5.5

LININA: The single crystal X-ray structural analysis reveals that LININA is a

1:1 cocrystal of LIN and INA. The tetrahedral coordination environment of the lithium
cations were achieved by three bridging carboxylates and the nitrate anions. If the fourmembered Li2(µ2-oxo)2 rings are considered as nodes, then the overall network could be
described as square grids.

These nodes are bridged by carboxylates, with each

carboxylate having one µ2-O donor and one monodentate O-donor. The Li-O coordinate
bond distances in LININA are 1.888, 1.931, 1.963 and 1.974 Å. The sheets (grids) stack
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along the a axis in AAA fashion and interact via hydrogen bonding. Distance between Li
atoms in adjacent sheets (measured along a axis) = 9.931 Å.

Figure 6.6 Representation of square grids in LININA.

6.3.6

LINNAC: Cocrystallization of LIN and NAC results in the formation of 1:1

cocrystals wherein the Li atoms and the carboxylate moieties form a 4-membered ring
with Li-O bond distance of 1.875 and 1.966 Å (Figure 6.7). LINNAC is isoreticular to
LININA.

There is no H-bonding between sheets, resulting in a greater intersheet

distance than LININA .

Figure 6.7 Illustration of 4-memebered ring in LINNAC.
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Distance between Li atoms in adjacent sheets (measured along a axis) = 10.326 Å.
(slightly > than LININA). There is intra sheet H-bonding instead. Two of the oxygen
atoms in the nitrate ion forms a bifurcated hydrogen bond with the N-H moiety of NAC
molecule (O···N-H: 2.815 and 2.993 Å). Similar to that of LININA, LINNAC also
results on formation of square grids (Figure 6.8).

Figure 6.8 Overall network in LINNAC.

6.5.7

LINDMG2: Cocrystallization of LIN with DMG resulst in the formation of a 1:2

cocrystal. Each of the Li atoms is coordinated to one of the oxygen atoms of the
carboxylate moieties of four DMG molecules with Li-O bond lengths of 1.934, 1.948,
1.952 and 1.951Å. The R2NH+ moiety of DMG involves in H-bonding with one of the
oxygen atoms of carboxylate moiety of DMG as represented in Figure 6.9. The nitrate
anion does not participate in any kind of bonding in LINDMG2. The overall bonding in
LINDMG2 resulst in the formation of a diamondoid network.
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Figure 6.9 Representation of overall packing in LINDMG2.

6.3.8

LINSER2: The single crystal X-ray structural analysis reveals that LINSER2 is a

1:2 cocrystal of lithium nitrate and L-serine. Each lithium cation is bridged by four
carboxylates to form an undulating square grid. Each ammonium cation (R3NH+) forms
hydrogen bond to the O-H functionalities of two adjacent L-serine molecules and a
nitrate anion. Figure 6.10 represents the asymmetric unit and Figure 6.11 the overall
network in LINSER2.

Figure 6.10 Asymmetric unit of LINSER2.
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Figure 6.11 Illustration of square grids in LINSER2.

6.4

Discussion

All the cocrystals of Li exhibit four-fold coordination (which is one of the most common
coordination numbers. From our study it is observed that there is considerable flexibility
in the overall geometry of the ionic cocrystals of Li salts with zwitterions (including
amino acids and molecules like INA and NAC). Table 6.1 lists all the ionic cocrystals of
Li salts with their stoichiometry and geometry. So far 26 ionic cocrystals (1:1, 1:2 and
2:3) of LIB, LIC and LIN have been isolated six of which are hydrated cocrystals.
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Table 6.1 List of ionic cocrystals of Li salts with their stoichiometry and geometry.

Ionic cocrystal
LIBPRO*
LICABA
LICBAL-I*
LICBAL-II
LICDMG**
LICLEU*
LICPRO*
LICSAR*
LINABA
LINBAL
LINDMG
LINHIS*
LININA

Stoichiometry
1:1
1:1
1:1
1:1
1:1
1:1
1:1
1:1
1:1
2:3
1:1
1:1
1:1

Geometry
1D Tape
1D Tape
1D Tape
1D Tape
Discrete
1D Tape
1D Tape
1D Tape
1D Tape
1D Tape
1D Tape
1D Tape
SQG

Ionic cocrystal
LINNAC
LINPRO
LINSAR
LIBDMG2
LIBPRO2
LICDMG2
LICPRO2
LICSAR2
LINBTN2
LINPRO2-I
LINPRO2-II
LINDMG2
LINSER2

Stoichiometry
1:1
1:1
1:1
1:2
1:2
1:2
1:2
1:2
1:2
1:2
1:2
1:2
1:2

Geometry
SQG
DIA
1D Tape
DIA
DIA
DIA
DIA
SQG
SQG
ABW
DIA
DIA
SQG

* = monohydrate, ** = dihydrate

Hydration is more frequently observed in 1:1 cocrystals of LIB and LIC. Only one of
LINs cocrystal, LINHIS, formed a hydrate the remaining are anhydrates. In LIN
cocrystals the Li atom is coordinated to three carboxylates and the fourth coordination is
satisfied by the nitrate ion which acts as the bridging ligand. On the contrary, in most of
the LIB and LIC cocrystals the fourth coordination is satisfied by a water molecule
(except LICABA and LICBAL-II). In LICABA and LICBAL-II the fourth
coordination is fulfilled by the Cl anion allowing no room for the water molecule to
coordinate to the metal ion. The Li ion in LICDMG is coordinated by only two
carboxylates which allows two water molecules to complete the tetrahedral coordination
of Li atom by forming a discrete unit of eight membered ring. From this it can be
estimated that LIN cocrystals are more resistant to hydration when compared to LIC and
LIB cocrystals.

Only one of LINs cocrystal, LINHIS is a monohydrate while the

remaining are anhydrates. The erratic nature of water molecule leads to the formation of
hydrates. More often in cocrystal design whenever there is an imbalance in the number of
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acceptors and donors, water molecules play role in satisfying the shortage thereby
resulting in cocrystal hydrates. The formation of hydrates has intrigued many researchers
and many have tried to address the frequency of formation32 including classification
based on their structure and energetics.33 One such classification was done by Morris and
Rodriguez-Hornedo34 where the hydrates were divided into three classes: a) channel
hydrates in which water molecules interact with each other and form tunnels within the
crystal lattice; b) isolated site hydrates in which water molecules are not directly
hydrogen bonded to each other; c) metal ion associated hydrates in which water
molecules form strong interactions with transition metals or alkali metals. Consequently,
the 1:1 cocrystal hydrates of Li salts fall into the third category where the water
molecules are coordinated to the metal. The only one cocrystal for which the anhydrate
form was producible is LICBAL-II. The 1:1 LIN cocrystals (except LINHIS) as well as
the 1:2 cocrystals escapes from forming hydrates in these cocrystals the lithium ion
coordinates to the oxygen atom of the carboxylate moieties or to the oxygen of the
bridging NO3- ion. In LINHIS the Li cation is coordinated to oxygen atoms of three
carboxylate moieties and the fourth coordination is fulfilled by water instead of the
nitrate anion which is quite unusual from the rest of the LIN 1:1 cocrystals wherein the
nitrate anion completes its coordination.
Owing to its variability in coordination number, Li complexes display a rich
divergence in their geometry from 0-periodic to 3-periodic. Out of sixteen 1:1 cocrystals,
twelve exhibit 1-D periodic tapes. In these twelve cocrystals (except LICBAL-II), the 1D tapes are formed by fused 6-membered rings whereas in LICBAL-II the tapes are
generated by the fusion of 8 and 4-membered rings. However, the overall geometry
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produced by 1:1 cocrystals are 1-D tapes. Only one cocrystal, LICDMG, forms a discrete
unit which is further involved in H-bonding in a 3-D network. Two cocrystals LININA
and LINNAC forms square grids and LINPRO exhibit diamondoid geometries. More
structural diversity is observed in 1:2 cocrystals which include topologies such as ABW,
diamondoids and square grids.
6.5

Conclusion

Ionic cocrystals represent a relatively underexplored class of cocrystals which can play
key role material chemistry. Ionic cocrystals of alkali metals especially metals like
lithium are quite intriguing as it exhibits a wide range of structural diversity due to its
small size. The oxophilic nature of lithium makes amino acids suitable cocrystal formers
due to the presence of carboxylate moiety. It is clear from this contribution that the
stoichiometry between the Li salts to the amino acid governs the periodicity of the
resulting cocrystals. All of the LIB and LIC 1:1 cocrystals generate 1-periodic structures
(1-D tapes) except LICDMG which forms a discrete unit (0-periodicity) and most of
them undergo hydration. Whereas equimolar quantities of LIN and amino acid result in
the formation of 1- periodic, 2- periodic (square grids) and 3-periodic structures
(diamondoid net). Thus, ionic cocrystals are important not only in terms of crystal
engineering perspective but also for pharmaceuticals especially zwitterionic drugs.
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Table 6.2 Crystallographic data and structure refinement parameters for the cocrystals

Formula
MW
Crystal system
Space group
a (Å)
b (Å)
c (Å)
 (deg)
 (deg)
 (deg)
V /Å3
Dc/mg m-3
Z
2 range
Nref./Npara.
T /K
R1 [I>2sigma(I)]
wR2
GOF
Abs coef.
Formula
MW
Crystal system
Space group
a (Å)
b (Å)
c (Å)
 (deg)
 (deg)
 (deg)
V /Å3
Dc/g cm-3
Z
2 range
Nref./Npara.
T /K
R1 [I>2sigma(I)]
wR2
GOF
Abs coef.

LICLEU
C6 H13ClLiNO3
191.43
P21
Monoclinic
13.215 (4)
4.9721 (15)
15.668 (4)
90
95.272 (16)
90
1025.1 (5)
1.228
4
2.83 to 65.36
2435/223
228 (2)
0.0782
0.1860
1.045
3.074
LININA
C6H5LiN2O5
192.06
P21/c
Monoclinic
9.9315 (6)
10.0382 (6)
7.5846 (5)
90
91.201 (4)
90
755.98 (8)
1.687
4
4.45 to 63.78
1250/127
293 (2)
0.0436
0.1097
0.923
1.278

LINABA
C4H9LiN2O5
172.07
P21/m
Monoclinic
4.87360 (10)
15.1136 (4)
10.2399 (3)
90
96.769 (2)
90
748.99(3)
1.526
4
5.24 to 68.12
1333/122
293 (2)
0.0429
0.1131
1.054
1.195
LINNAC
C4H3Li0.67N4O2
143.73
P21/c
Monoclinic
10.320 (3)
9.894 (3)
7.387 (2)
90
90.803 (15)
90
754.2(4)
1.899
4
4.28 to 66.71
1277/128
293 (2)
0.0890
0.2257
0.999
1.325
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LINBAL
C9H21Li2N5O12
405.19
Pca21
Orthorhombic
13.290 (2)
5.0444 (9)
26.107 (5)
90
90
90
1750.2 (5)
1.538
4
3.39 to 66.70
278/256
293 (2)
0.0677
0.1596
1.043
1.222
LINSER2
C6H14LiN3O9
279.14
P212121
Orthorhombic
4.8395 (4)
8.7210 (6)
26.4305 (18)
90
90
90
1115.51 (14)
1.662
4
3.34 to 67.88
1950/217
100 (2)
0.0326
0.1071
0.637
1.366

LINHIS
C6H9LiN4O6
240.11
P21
Monoclinic
7.5068 (9)
5.0385 (6)
13.6693 (16)
90
95.722 (5)
90
514.44 (11)
1.550
2
3.25 to 66.11
1674 /161
293 (2)
0.0658
0.1687
1.049
1.192
LINDMG2
C8H18LiN3O7
275.19
Cc
Monoclinic
12.380 (4)
15.055 (3)
9.442 (4)
90
129.875 (14)
90
1350.5 (7)
1.353
4
5.51 to 65.07
2180/176
100 (2)
0.0860
0.2062
1.053
1.002
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Solid state characterization of CFAINM•2H2O
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Solid state characterization of CFAINZ
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Solid state characterization of CFAGAH
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Solid state characterization of EGLDMP
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Solid state characterization of EGLGAH
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Solid state characterization of EGLINZ•2H2O

IR

DSC

1.4
1.2

Relative intensity

1.0
0.8
0.6
EGLINZ.2H2O_Expt

0.4
0.2
EGLINZ.2H2O_Cal

0.0
5

10

15

20

25

30

35

40

2

PXRD

TGA

171

Solid state characterization of MGLGAH
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Solid state characterization of MGLINZ
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Solid state characterization of PCAGAH
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Solid state characterization of PGLDMP
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Solid state characterization of PGLGAH•2H2O
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Solid state characterization of COUNAM
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Solid state characterization of COUINM-I
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Solid state characterization of COUINM-II
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Solid state characterization of COUINZ

DSC

IR

1.2

Relative intensity

1.0

0.8

0.6

0.4

0.2

Expt

0.0

Calc

5

10

15

20

25

30

35

40

2

PXRD

TGA

180

Solid state characterization of COUTHP-III
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Solid state characterization of COUTBR•2H2O
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Solid state characterization of COUTBR
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Solid state characterization of COUURE

DSC

IR

1.6
1.4

Relative intensity

1.2
1.0
0.8

COUURE_Expt (298 K)

0.6
0.4
COUURE_Cal (100 K)

0.2
0.0
5

10

15

20

25

30

35

40

2

PXRD

TGA

184

Solid state characterization of COUBTN
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Solid state characterization of COUINA
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Solid state characterization of HCTNAC
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Solid state characterization of HCTBTN
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Solid state characterization of HCTDMG
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Solid state characterization of LINABA
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Solid state characterization of LINBAL
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Solid state characterization of LINHIS
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Solid state characterization of LININA
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Solid state characterization of LINNAC
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Solid state characterization of LINSER2
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